1
|
Burns N, Nijmeh H, Lapel M, Riddle S, Yegutkin GG, Stenmark KR, Gerasimovskaya E. Isolation of vasa vasorum endothelial cells from pulmonary artery adventitia: Implementation to vascular biology research. Microvasc Res 2023; 147:104479. [PMID: 36690271 DOI: 10.1016/j.mvr.2023.104479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 01/06/2023] [Accepted: 01/17/2023] [Indexed: 01/22/2023]
Abstract
Isolated endothelial cells are valuable in vitro model for vascular research. At present, investigation of disease-relevant changes in vascular endothelium at the molecular level requires established endothelial cell cultures, preserving vascular bed-specific phenotypic characteristics. Vasa vasorum (VV) form a microvascular network around large blood vessels, in both the pulmonary and systemic circulations, that are critically important for maintaining the integrity and oxygen supply of the vascular wall. However, despite the pathophysiological significance of the VV, methods for the isolation and culture of vasa vasorum endothelial cells (VVEC) have not yet been reported. In our prior studies, we demonstrated the presence of hypoxia-induced angiogenic expansion of the VV in the pulmonary artery (PA) of neonatal calves; an observation which has been followed by a series of in vitro studies on isolated PA VVEC. Here we present a detailed protocol for reproducible isolation, purification, and culture of PA VVEC. We show these cells to express generic endothelial markers, (vWF, eNOS, VEGFR2, Tie1, and CD31), as well as progenitor markers (CD34 and CD133), bind lectin Lycopersicon Esculentum, and incorporate acetylated low-density lipoproteins labeled with acetylated LDL (DiI-Ac-LDL). qPCR analysis additionally revealed the expression of CD105, VCAM-1, ICAM-1, MCAM, and NCAM. Ultrastructural electron microscopy and immunofluorescence staining demonstrated that VVEC are morphologically characterized by a developed actin and microtubular cytoskeleton, mitochondrial network, abundant intracellular vacuolar/secretory system, and cell-surface filopodia. VVEC exhibit exponential growth in culture and can be mitogenically activated by multiple growth factors. Thus, our protocol provides the opportunity for VVEC isolation from the PA, and potentially from other large vessels, enabling advances in VV research.
Collapse
Affiliation(s)
- Nana Burns
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America
| | - Hala Nijmeh
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America
| | - Martin Lapel
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America
| | - Suzette Riddle
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America
| | - Gennady G Yegutkin
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland
| | - Kurt R Stenmark
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America
| | - Evgenia Gerasimovskaya
- Department of Pediatric Critical Care Medicine, University of Colorado Denver, Aurora, CO, United States of America.
| |
Collapse
|
2
|
Abstract
Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic processes, including immunomodulation and cell proliferation. Tumors create an adenosine-rich immunosuppressive microenvironment through the increased release of ATP from dying and stressed cells and its ectoenzymatic conversion into adenosine. Therefore, the adenosine pathway becomes an important therapeutic target to improve the effectiveness of immune therapies. Prior research has focused largely on the two major ectonucleotidases, ectonucleoside triphosphate diphosphohydrolase 1/cluster of differentiation (CD)39 and ecto-5'-nucleotidase/CD73, which catalyze the breakdown of extracellular ATP into adenosine, and on the subsequent activation of different subtypes of adenosine receptors with mixed findings of antitumor and protumor effects. New findings, needed for more effective therapeutic approaches, require consideration of redundant pathways controlling intratumoral adenosine levels, including the alternative NAD-inactivating pathway through the CD38-ectonucleotide pyrophosphatase phosphodiesterase (ENPP)1-CD73 axis, the counteracting ATP-regenerating ectoenzymatic pathway, and cellular adenosine uptake and its phosphorylation by adenosine kinase. This review provides a holistic view of extracellular and intracellular adenosine metabolism as an integrated complex network and summarizes recent data on the underlying mechanisms through which adenosine and its precursors ATP and ADP control cancer immunosurveillance, tumor angiogenesis, lymphangiogenesis, cancer-associated thrombosis, blood flow, and tumor perfusion. Special attention is given to differences and commonalities in the purinome of different cancers, heterogeneity of the tumor microenvironment, subcellular compartmentalization of the adenosine system, and novel roles of purine-converting enzymes as targets for cancer therapy. SIGNIFICANCE STATEMENT: The discovery of the role of adenosine as immune checkpoint regulator in cancer has led to the development of novel therapeutic strategies targeting extracellular adenosine metabolism and signaling in multiple clinical trials and preclinical models. Here we identify major gaps in knowledge that need to be filled to improve the therapeutic gain from agents targeting key components of the adenosine metabolic network and, on this basis, provide a holistic view of the cancer purinome as a complex and integrated network.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland (G.G.Y.); Department of Neurosurgery, Robert Wood Johnson and New Jersey Medical Schools, Rutgers University, Piscataway, New Jersey (D.B.); and Rutgers Brain Health Institute, Piscataway, New Jersey (D.B.)
| | - Detlev Boison
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland (G.G.Y.); Department of Neurosurgery, Robert Wood Johnson and New Jersey Medical Schools, Rutgers University, Piscataway, New Jersey (D.B.); and Rutgers Brain Health Institute, Piscataway, New Jersey (D.B.)
| |
Collapse
|
3
|
Jacobson KA, Scortichini M, Idris RM, Moschütz S, Keim A, Salmaso VA, Dobelmann C, Oliva PA, Losenkova K, Irjala H, Vaittinen S, Sandholm J, Yegutkin GG, Sträter N, Junker A, Müller CE. Structure activity relationship of 3‐methylcytidine‐5’‐α,β‐methylenediphosphates as CD73 inhibitors. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r3981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | - Susanne Moschütz
- Center for Biotechnology and BiomedicineUniversity of LeipzigLeipzig
| | - Antje Keim
- Center for Biotechnology and BiomedicineUniversity of LeipzigLeipzig
| | | | - Clemens Dobelmann
- European Institute for Molecular ImagingUniversity of MünsterMünster
| | | | | | - Heikki Irjala
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryTurku University Hospital and Turku UniversityTurku
| | | | | | | | - Norbert Sträter
- Center for Biotechnology and BiomedicineUniversity of LeipzigLeipzig
| | - Anna Junker
- European Institute for Molecular ImagingUniversity of MünsterMünster
| | | |
Collapse
|
4
|
Losenkova K, Takeda A, Ragauskas S, Cerrada-Gimenez M, Vähätupa M, Kaja S, Paul ML, Schmies CC, Rolshoven G, Müller CE, Sandholm J, Jalkanen S, Kalesnykas G, Yegutkin GG. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity. Cell Mol Life Sci 2022; 79:152. [PMID: 35212809 PMCID: PMC8881442 DOI: 10.1007/s00018-022-04187-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 01/28/2022] [Accepted: 02/04/2022] [Indexed: 01/03/2023]
Abstract
ATP and adenosine have emerged as important signaling molecules involved in vascular remodeling, retinal functioning and neurovascular coupling in the mammalian eye. However, little is known about the regulatory mechanisms of purinergic signaling in the eye. Here, we used three-dimensional multiplexed imaging, in situ enzyme histochemistry, flow cytometric analysis, and single cell transcriptomics to characterize the whole pattern of purine metabolism in mouse and human eyes. This study identified ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39), NTPDase2, and ecto-5′-nucleotidase/CD73 as major ocular ecto-nucleotidases, which are selectively expressed in the photoreceptor layer (CD73), optic nerve head, retinal vasculature and microglia (CD39), as well as in neuronal processes and cornea (CD39, NTPDase2). Specifically, microglial cells can create a spatially arranged network in the retinal parenchyma by extending and retracting their branched CD39high/CD73low processes and forming local “purinergic junctions” with CD39low/CD73− neuronal cell bodies and CD39high/CD73− retinal blood vessels. The relevance of the CD73–adenosine pathway was confirmed by flash electroretinography showing that pharmacological inhibition of adenosine production by injection of highly selective CD73 inhibitor PSB-12489 in the vitreous cavity of dark-adapted mouse eyes rendered the animals hypersensitive to prolonged bright light, manifested as decreased a-wave and b-wave amplitudes. The impaired electrical responses of retinal cells in PSB-12489-treated mice were not accompanied by decrease in total thickness of the retina or death of photoreceptors and retinal ganglion cells. Our study thus defines ocular adenosine metabolism as a complex and spatially integrated network and further characterizes the critical role of CD73 in maintaining the functional activity of retinal cells.
Collapse
Affiliation(s)
- Karolina Losenkova
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Tykistökatu 6A, 20520, Turku, Finland
| | - Akira Takeda
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Tykistökatu 6A, 20520, Turku, Finland
| | | | | | | | - Simon Kaja
- Experimentica Ltd., Kuopio, Finland.,Department of Ophthalmology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
| | - Marius L Paul
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.,Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical and Medicinal Chemistry, University of Bonn, Bonn, Germany
| | - Constanze C Schmies
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical and Medicinal Chemistry, University of Bonn, Bonn, Germany
| | - Georg Rolshoven
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical and Medicinal Chemistry, University of Bonn, Bonn, Germany
| | - Christa E Müller
- Pharma Center Bonn, Pharmaceutical Institute, Pharmaceutical and Medicinal Chemistry, University of Bonn, Bonn, Germany
| | - Jouko Sandholm
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
| | - Sirpa Jalkanen
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Tykistökatu 6A, 20520, Turku, Finland
| | | | - Gennady G Yegutkin
- MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Tykistökatu 6A, 20520, Turku, Finland.
| |
Collapse
|
5
|
Kobayashi D, Sugiura Y, Umemoto E, Takeda A, Ueta H, Hayasaka H, Matsuzaki S, Katakai T, Suematsu M, Hamachi I, Yegutkin GG, Salmi M, Jalkanen S, Miyasaka M. Extracellular ATP Limits Homeostatic T Cell Migration Within Lymph Nodes. Front Immunol 2022; 12:786595. [PMID: 35003105 PMCID: PMC8728011 DOI: 10.3389/fimmu.2021.786595] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 12/03/2021] [Indexed: 12/20/2022] Open
Abstract
Whereas adenosine 5'-triphosphate (ATP) is the major energy source in cells, extracellular ATP (eATP) released from activated/damaged cells is widely thought to represent a potent damage-associated molecular pattern that promotes inflammatory responses. Here, we provide suggestive evidence that eATP is constitutively produced in the uninflamed lymph node (LN) paracortex by naïve T cells responding to C-C chemokine receptor type 7 (CCR7) ligand chemokines. Consistently, eATP was markedly reduced in naïve T cell-depleted LNs, including those of nude mice, CCR7-deficient mice, and mice subjected to the interruption of the afferent lymphatics in local LNs. Stimulation with a CCR7 ligand chemokine, CCL19, induced ATP release from LN cells, which inhibited CCR7-dependent lymphocyte migration in vitro by a mechanism dependent on the purinoreceptor P2X7 (P2X7R), and P2X7R inhibition enhanced T cell retention in LNs in vivo. These results collectively indicate that paracortical eATP is produced by naïve T cells in response to constitutively expressed chemokines, and that eATP negatively regulates CCR7-mediated lymphocyte migration within LNs via a specific subtype of ATP receptor, demonstrating its fine-tuning role in homeostatic cell migration within LNs.
Collapse
Affiliation(s)
- Daichi Kobayashi
- Department of Immunology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.,Department of Pharmacology, Wakayama Medical University, Wakayama, Japan
| | - Yuki Sugiura
- Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
| | - Eiji Umemoto
- Laboratory of Microbiology and Immunology, University of Shizuoka, Shizuoka, Japan
| | - Akira Takeda
- MediCity Research Laboratory, University of Turku, Turku, Finland
| | - Hisashi Ueta
- Department of Anatomy, School of Medicine, Dokkyo Medical University, Tochigi, Japan
| | - Haruko Hayasaka
- Laboratory of Immune Molecular Function, Faculty of Science and Engineering, Kindai University, Higashi-Osaka, Japan
| | - Shinsuke Matsuzaki
- Department of Pharmacology, Wakayama Medical University, Wakayama, Japan.,Department of Radiological Sciences, Morinomiya University of Medical Sciences, Osaka, Japan
| | - Tomoya Katakai
- Department of Immunology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Makoto Suematsu
- Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
| | - Itaru Hamachi
- Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan
| | | | - Marko Salmi
- MediCity Research Laboratory, University of Turku, Turku, Finland.,Institute of Biomedicine, University of Turku, Turku, Finland
| | - Sirpa Jalkanen
- MediCity Research Laboratory, University of Turku, Turku, Finland
| | - Masayuki Miyasaka
- MediCity Research Laboratory, University of Turku, Turku, Finland.,Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Suita, Japan.,World Premier International (WPI) Immunology Frontier Research Center, Osaka University, Suita, Japan
| |
Collapse
|
6
|
Scortichini M, Idris RM, Moschütz S, Keim A, Salmaso V, Dobelmann C, Oliva P, Losenkova K, Irjala H, Vaittinen S, Sandholm J, Yegutkin GG, Sträter N, Junker A, Müller CE, Jacobson KA. Structure-Activity Relationship of 3-Methylcytidine-5'-α,β-methylenediphosphates as CD73 Inhibitors. J Med Chem 2022; 65:2409-2433. [PMID: 35080883 PMCID: PMC8865918 DOI: 10.1021/acs.jmedchem.1c01852] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We recently reported N4-substituted 3-methylcytidine-5'-α,β-methylenediphosphates as CD73 inhibitors, potentially useful in cancer immunotherapy. We now expand the structure-activity relationship of pyrimidine nucleotides as human CD73 inhibitors. 4-Chloro (MRS4598 16; Ki = 0.673 nM) and 4-iodo (MRS4620 18; Ki = 0.436 nM) substitution of the N4-benzyloxy group decreased Ki by ∼20-fold. Primary alkylamine derivatives coupled through a p-amido group with a varying methylene chain length (24 and 25) were functionalized congeners, for subsequent conjugation to carrier or reporter moieties. X-ray structures of hCD73 with two inhibitors indicated a ribose ring conformational adaptation, and the benzyloxyimino group (E configuration) binds to the same region (between the C-terminal and N-terminal domains) as N4-benzyl groups in adenine inhibitors. Molecular dynamics identified stabilizing interactions and predicted conformational diversity. Thus, by N4-benzyloxy substitution, we have greatly enhanced the inhibitory potency and added functionality enabling molecular probes. Their potential as anticancer drugs was confirmed by blocking CD73 activity in tumor tissues in situ.
Collapse
Affiliation(s)
- Mirko Scortichini
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Riham Mohammed Idris
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Susanne Moschütz
- Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany
| | - Antje Keim
- Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany
| | - Veronica Salmaso
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Clemens Dobelmann
- European Institute for Molecular Imaging (EIMI), University of Münster, Waldeyerstrasse 15, D-48149 Münster, Germany
| | - Paola Oliva
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| | | | - Heikki Irjala
- Department of Otorhinolaryngology-Head and Neck Surgery, Turku University Hospital and Turku University, 20520 Turku, Finland
| | - Samuli Vaittinen
- Department of Pathology, Turku University Hospital and Turku University, 20520 Turku, Finland
| | - Jouko Sandholm
- Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland
| | | | - Norbert Sträter
- Center for Biotechnology and Biomedicine, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany
| | - Anna Junker
- European Institute for Molecular Imaging (EIMI), University of Münster, Waldeyerstrasse 15, D-48149 Münster, Germany
| | - Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Kenneth A Jacobson
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States
| |
Collapse
|
7
|
Spatola BN, Lerner AG, Wong C, Dela Cruz T, Welch M, Fung W, Kovalenko M, Losenkova K, Yegutkin GG, Beers C, Corbin J, Soros VB. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism. MAbs 2021; 12:1838036. [PMID: 33146056 PMCID: PMC7646477 DOI: 10.1080/19420862.2020.1838036] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The extracellular ATP/adenosine axis in the tumor microenvironment (TME) has emerged as an important immune-regulatory pathway. Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), otherwise known as CD39, is highly expressed in the TME, both on infiltrating immune cells and tumor cells across a broad set of cancer indications. CD39 processes pro-inflammatory extracellular ATP to ADP and AMP, which is then processed by Ecto-5ʹ-nucleotidase/CD73 to immunosuppressive adenosine. Directly inhibiting the enzymatic function of CD39 via an antibody has the potential to unleash an immune-mediated anti-tumor response via two mechanisms: 1) increasing the availability of immunostimulatory extracellular ATP released by damaged and/or dying cells, and 2) reducing the generation and accumulation of suppressive adenosine within the TME. Tizona Therapeutics has engineered a novel first-in-class fully human anti-CD39 antibody, TTX-030, that directly inhibits CD39 ATPase enzymatic function with sub-nanomolar potency. Further characterization of the mechanism of inhibition by TTX-030 using CD39+ human melanoma cell line SK-MEL-28 revealed an uncompetitive allosteric mechanism (α < 1). The uncompetitive mechanism of action enables TTX-030 to inhibit CD39 at the elevated ATP concentrations reported in the TME. Maximal inhibition of cellular CD39 ATPase velocity was 85%, which compares favorably to results reported for antibody inhibitors to other enzyme targets. The allosteric mechanism of TTX-030 was confirmed via mapping the epitope to a region of CD39 distant from its active site, which suggests possible models for how potent inhibition is achieved. In summary, TTX-030 is a potent allosteric inhibitor of CD39 ATPase activity that is currently being evaluated in clinical trials for cancer therapy.
Collapse
Affiliation(s)
- Bradley N Spatola
- Antibody Development, Tizona Therapeutics , South San Francisco, CA, USA
| | - Alana G Lerner
- Immunology, Tizona Therapeutics , South San Francisco, CA, USA
| | - Clifford Wong
- Antibody Development, Tizona Therapeutics , South San Francisco, CA, USA
| | - Tracy Dela Cruz
- Immunology, Tizona Therapeutics , South San Francisco, CA, USA.,Immunology, Trishula Therapeutics, South San Francisco , CA, USA
| | - Megan Welch
- Immunology, Tizona Therapeutics , South San Francisco, CA, USA
| | - Wanchi Fung
- Antibody Development, Tizona Therapeutics , South San Francisco, CA, USA
| | | | | | | | - Courtney Beers
- Immunology, Tizona Therapeutics , South San Francisco, CA, USA
| | - John Corbin
- Antibody Development, Tizona Therapeutics , South San Francisco, CA, USA
| | - Vanessa B Soros
- Antibody Development, Tizona Therapeutics , South San Francisco, CA, USA
| |
Collapse
|
8
|
Abstract
The concept of extracellular purinergic signaling was first proposed by Geoffrey Burnstock in the early 1970s. Since then, extracellular ATP and its metabolites ADP and adenosine have attracted an enormous amount of attention in terms of their involvement in a wide range of immunomodulatory, thromboregulatory, angiogenic, vasoactive and other pathophysiological activities in different organs and tissues, including the vascular system. In addition to significant progress in understanding the properties of nucleotide- and adenosine-selective receptors, recent studies have begun to uncover the complexity of regulatory mechanisms governing the duration and magnitude of the purinergic signaling cascade. This knowledge has led to the development of new paradigms in understanding the entire purinome by taking into account the multitude of signaling and metabolic pathways involved in biological effects of ATP and adenosine and compartmentalization of the adenosine system. Along with the "canonical route" of ATP breakdown to adenosine via sequential ecto-nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities, it has now become clear that purine metabolism is the result of concerted effort between ATP release, its metabolism through redundant nucleotide-inactivating and counteracting ATP-regenerating ectoenzymatic pathways, as well as cellular nucleoside uptake and phosphorylation of adenosine to ATP through complex phosphotransfer reactions. In this review I provide an overview of key enzymes involved in adenosine metabolic network, with special emphasis on the emerging roles of purine-converting ectoenzymes as novel targets for cancer and vascular therapies.
Collapse
|
9
|
Schmies CC, Rolshoven G, Idris RM, Losenkova K, Renn C, Schäkel L, Al-Hroub H, Wang Y, Garofano F, Schmidt-Wolf IGH, Zimmermann H, Yegutkin GG, Müller CE. Fluorescent Probes for Ecto-5'-nucleotidase (CD73). ACS Med Chem Lett 2020; 11:2253-2260. [PMID: 33214837 DOI: 10.1021/acsmedchemlett.0c00391] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 09/03/2020] [Indexed: 12/22/2022] Open
Abstract
Ecto-5'-nucleotidase (CD73) catalyzes the hydrolysis of AMP to anti-inflammatory, immunosuppressive adenosine. It is expressed on vascular endothelial, epithelial, and also numerous cancer cells where it strongly contributes to an immunosuppressive microenvironment. In the present study we designed and synthesized fluorescent-labeled CD73 inhibitors with low nanomolar affinity and high selectivity based on N 6 -benzyl-α,β-methylene-ADP (PSB-12379) as a lead structure. Fluorescein was attached to the benzyl residue via different linkers resulting in PSB-19416 (14b, K i 12.6 nM) and PSB-18332 (14a, K i 2.98 nM) as fluorescent high-affinity probes for CD73. These compounds are anticipated to become useful tools for biological studies, drug screening, and diagnostic applications.
Collapse
Affiliation(s)
- Constanze C. Schmies
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Georg Rolshoven
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Riham M. Idris
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | | | - Christian Renn
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Laura Schäkel
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Haneen Al-Hroub
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Yulu Wang
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn D-53127, Germany
| | - Francesca Garofano
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn D-53127, Germany
| | - Ingo G. H. Schmidt-Wolf
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn D-53127, Germany
| | - Herbert Zimmermann
- Institute of Cell Biology and Neuroscience, Goethe-University, D-60438 Frankfurt am Main, Germany
| | | | - Christa E. Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| |
Collapse
|
10
|
Losenkova K, Zuccarini M, Karikoski M, Laurila J, Boison D, Jalkanen S, Yegutkin GG. Compartmentalization of adenosine metabolism in cancer cells and its modulation during acute hypoxia. J Cell Sci 2020; 133:jcs241463. [PMID: 32317394 PMCID: PMC10681022 DOI: 10.1242/jcs.241463] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Accepted: 04/02/2020] [Indexed: 12/20/2022] Open
Abstract
Extracellular adenosine mediates diverse anti-inflammatory, angiogenic and vasoactive effects, and has become an important therapeutic target for cancer, which has been translated into clinical trials. This study was designed to comprehensively assess adenosine metabolism in prostate and breast cancer cells. We identified cellular adenosine turnover as a complex cascade, comprising (1) the ectoenzymatic breakdown of ATP via sequential ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1, officially known as ENPP1), ecto-5'-nucleotidase (CD73, also known as NT5E), and adenosine deaminase reactions, and ATP re-synthesis through a counteracting adenylate kinase and members of the nucleoside diphosphate kinase (NDPK, also known as NME/NM23) family; (2) the uptake of nucleotide-derived adenosine via equilibrative nucleoside transporters; and (3) the intracellular adenosine phosphorylation into ATP by adenosine kinase and other nucleotide kinases. The exposure of cancer cells to 1% O2 for 24 h triggered an ∼2-fold upregulation of CD73, without affecting nucleoside transporters, adenosine kinase activity and cellular ATP content. The ability of adenosine to inhibit the tumor-initiating potential of breast cancer cells via a receptor-independent mechanism was confirmed in vivo using a xenograft mouse model. The existence of redundant pathways controlling extracellular and intracellular adenosine provides a sufficient justification for reexamination of the current concepts of cellular purine homeostasis and signaling in cancer.This article has an associated First Person interview with the first author of the paper.
Collapse
Affiliation(s)
| | - Mariachiara Zuccarini
- MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
- Department of Medical, Oral and Biotechnological Sciences, 'G. D'Annunzio' University of Chieti-Pescara, 66100 Chieti, Italy
| | - Marika Karikoski
- MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
| | - Juha Laurila
- MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
| | - Detlev Boison
- Department of Neurosurgery, Robert Wood Johnson and New Jersey Medical Schools, Rutgers University, Piscataway, NJ 08854, USA
| | - Sirpa Jalkanen
- MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
| | | |
Collapse
|
11
|
Abstract
Adenosine is a key metabolic and immune-checkpoint regulator implicated in the tumor escape from the host immune system. Major gaps in knowledge that impede the development of effective adenosine-based therapeutics include: (1) lack of consideration of redundant pathways controlling ATP and adenosine levels; (2) lack of distinction between receptor-dependent and -independent effects of adenosine, and (3) focus on extracellular adenosine without consideration of intracellular metabolism and compartmentalization. In light of current clinical trials, we provide an overview of adenosine metabolism and point out the need for a more careful evaluation of the entire purinome in emerging cancer therapies.
Collapse
Affiliation(s)
- Detlev Boison
- Department of Neurosurgery, Robert Wood Johnson & New Jersey Medical Schools, Rutgers University, Piscataway, NJ 08854, USA; Rutgers Brain Health Institute, Piscataway, NJ 08854, USA.
| | - Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, 20520, Finland.
| |
Collapse
|
12
|
Bhattarai S, Pippel J, Meyer A, Freundlieb M, Schmies C, Abdelrahman A, Fiene A, Lee S, Zimmermann H, El‐Tayeb A, Yegutkin GG, Sträter N, Müller CE. X‐Ray Co‐Crystal Structure Guides the Way to Subnanomolar Competitive Ecto‐5′‐Nucleotidase (CD73) Inhibitors for Cancer Immunotherapy. Adv Therap 2019. [DOI: 10.1002/adtp.201900075] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Sanjay Bhattarai
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Jan Pippel
- Institute of Bioanalytical ChemistryCenter for Biotechnology and BiomedicineLeipzig University Deutscher Platz 5 04103 Leipzig Germany
| | - Anne Meyer
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Marianne Freundlieb
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Constanze Schmies
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Aliaa Abdelrahman
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Amelie Fiene
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Sang‐Yong Lee
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | - Herbert Zimmermann
- Institute of Cell Biology and NeuroscienceGoethe‐University Frankfurt am Main Germany
| | - Ali El‐Tayeb
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| | | | - Norbert Sträter
- Institute of Bioanalytical ChemistryCenter for Biotechnology and BiomedicineLeipzig University Deutscher Platz 5 04103 Leipzig Germany
| | - Christa E. Müller
- PharmaCenter Bonn, Pharmaceutical InstituteDepartment of Pharmaceutical & Medicinal ChemistryUniversity of Bonn An der Immenburg 4 D‐53121 Bonn Germany
| |
Collapse
|
13
|
Junker A, Renn C, Dobelmann C, Namasivayam V, Jain S, Losenkova K, Irjala H, Duca S, Balasubramanian R, Chakraborty S, Börgel F, Zimmermann H, Yegutkin GG, Müller CE, Jacobson KA. Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. J Med Chem 2019; 62:3677-3695. [PMID: 30895781 DOI: 10.1021/acs.jmedchem.9b00164] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Cluster of differentiation 73 (CD73) converts adenosine 5'-monophosphate to immunosuppressive adenosine, and its inhibition was proposed as a new strategy for cancer treatment. We synthesized 5'- O-[(phosphonomethyl)phosphonic acid] derivatives of purine and pyrimidine nucleosides, which represent nucleoside diphosphate analogues, and compared their CD73 inhibitory potencies. In the adenine series, most ribose modifications and 1-deaza and 3-deaza were detrimental, but 7-deaza was tolerated. Uracil substitution with N3-methyl, but not larger groups, or 2-thio, was tolerated. 1,2-Diphosphono-ethyl modifications were not tolerated. N4-(Aryl)alkyloxy-cytosine derivatives, especially with bulky benzyloxy substituents, showed increased potency. Among the most potent inhibitors were the 5'- O-[(phosphonomethyl)phosphonic acid] derivatives of 5-fluorouridine (4l), N4-benzoyl-cytidine (7f), N4-[ O-(4-benzyloxy)]-cytidine (9h), and N4-[ O-(4-naphth-2-ylmethyloxy)]-cytidine (9e) ( Ki values 5-10 nM at human CD73). Selected compounds tested at the two uridine diphosphate-activated P2Y receptor subtypes showed high CD73 selectivity, especially those with large nucleobase substituents. These nucleotide analogues are among the most potent CD73 inhibitors reported and may be considered for development as parenteral drugs.
Collapse
Affiliation(s)
- Anna Junker
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States.,PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , D-53121 Bonn , Germany.,European Institute for Molecular Imaging (EIMI) , University of Münster , Waldeyerstr. 15 , D-48149 Münster , Germany
| | - Christian Renn
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Clemens Dobelmann
- European Institute for Molecular Imaging (EIMI) , University of Münster , Waldeyerstr. 15 , D-48149 Münster , Germany
| | - Vigneshwaran Namasivayam
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Shanu Jain
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States
| | - Karolina Losenkova
- Medicity Research Laboratory , University of Turku , 20520 Turku , Finland
| | - Heikki Irjala
- Department of Otorhinolaryngology-Head and Neck Surgery , Turku University Hospital and Turku University , 20520 Turku , Finland
| | - Sierra Duca
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States
| | - Ramachandran Balasubramanian
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States
| | - Saibal Chakraborty
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States
| | - Frederik Börgel
- Institute for Pharmaceutical and Medicinal Chemistry , University of Münster , Correnstr. 48 , D-48149 Münster , Germany
| | - Herbert Zimmermann
- Institute of Cell Biology and Neuroscience , Goethe-University , D-60438 Frankfurt am Main , Germany
| | - Gennady G Yegutkin
- Medicity Research Laboratory , University of Turku , 20520 Turku , Finland
| | - Christa E Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , D-53121 Bonn , Germany
| | - Kenneth A Jacobson
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases , National Institutes of Health , Bethesda , Maryland 20892 , United States
| |
Collapse
|
14
|
Kauffenstein G, Yegutkin GG, Khiati S, Pomozi V, Le Saux O, Leftheriotis G, Lenaers G, Henrion D, Martin L. Alteration of Extracellular Nucleotide Metabolism in Pseudoxanthoma Elasticum. J Invest Dermatol 2018; 138:1862-1870. [PMID: 29501384 DOI: 10.1016/j.jid.2018.02.023] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2017] [Revised: 02/02/2018] [Accepted: 02/15/2018] [Indexed: 01/06/2023]
Abstract
Pseudoxanthoma elasticum (PXE) is a rare genetic condition primarily caused by hepatic ABCC6 transporter dysfunction. Most clinical manifestations of PXE are due to premature calcification of elastic fibers. However, the vascular impact of PXE is pleiotropic and remains ill defined. ABCC6 expression has recently been associated with cellular nucleotide export. We studied the impact of ABCC6 deficiency on blood levels of adenosine triphosphate and related metabolites and on soluble nucleotidase activities in PXE patients and Abcc6-/- mice. In addition, we investigated the expression of genes encoding ectocellular purinergic signaling proteins in mouse liver and aorta. Plasma adenosine triphosphate and pyrophosphate levels were significantly reduced in PXE patients and in Abcc6-/- mice, whereas adenosine concentration was not modified. Moreover, 5'-nucleotidase/CD73 activity was increased in the serum of PXE patients and Abcc6-/- mice. Consistent with alterations of purinergic signaling, the expression of genes involved in purine and phosphate transport/metabolism was dramatically modified in Abcc6-/- mouse aorta, with much less impact on the liver. ABCC6 deficiency causes impaired vascular homeostasis and tissue perfusion. Our findings suggest that these alterations are linked to changes in extracellular nucleotide metabolism that are remote from the liver. This opens new perspectives for the understanding of PXE pathophysiology.
Collapse
Affiliation(s)
- Gilles Kauffenstein
- MITOVASC-UMR CNRS 6015 INSERM U1083, Angers University, France; University Hospital of Angers, Angers, France.
| | - Gennady G Yegutkin
- Department of Microbiology and Immunology, MediCity Research Laboratory, University of Turku, Finland
| | - Salim Khiati
- MITOVASC-UMR CNRS 6015 INSERM U1083, Angers University, France
| | - Viola Pomozi
- Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
| | - Olivier Le Saux
- Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
| | | | - Guy Lenaers
- MITOVASC-UMR CNRS 6015 INSERM U1083, Angers University, France
| | - Daniel Henrion
- MITOVASC-UMR CNRS 6015 INSERM U1083, Angers University, France
| | - Ludovic Martin
- MITOVASC-UMR CNRS 6015 INSERM U1083, Angers University, France; University Hospital of Angers, Angers, France
| |
Collapse
|
15
|
Song A, Zhang Y, Han L, Yegutkin GG, Liu H, Sun K, D'Alessandro A, Li J, Karmouty-Quintana H, Iriyama T, Weng T, Zhao S, Wang W, Wu H, Nemkov T, Subudhi AW, Jameson-Van Houten S, Julian CG, Lovering AT, Hansen KC, Zhang H, Bogdanov M, Dowhan W, Jin J, Kellems RE, Eltzschig HK, Blackburn M, Roach RC, Xia Y. Erythrocytes retain hypoxic adenosine response for faster acclimatization upon re-ascent. Nat Commun 2017; 8:14108. [PMID: 28169986 PMCID: PMC5309698 DOI: 10.1038/ncomms14108] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 11/29/2016] [Indexed: 12/19/2022] Open
Abstract
Faster acclimatization to high altitude upon re-ascent is seen in humans; however, the molecular basis for this enhanced adaptive response is unknown. We report that in healthy lowlanders, plasma adenosine levels are rapidly induced by initial ascent to high altitude and achieved even higher levels upon re-ascent, a feature that is positively associated with quicker acclimatization. Erythrocyte equilibrative nucleoside transporter 1 (eENT1) levels are reduced in humans at high altitude and in mice under hypoxia. eENT1 deletion allows rapid accumulation of plasma adenosine to counteract hypoxic tissue damage in mice. Adenosine signalling via erythrocyte ADORA2B induces PKA phosphorylation, ubiquitination and proteasomal degradation of eENT1. Reduced eENT1 resulting from initial hypoxia is maintained upon re-ascent in humans or re-exposure to hypoxia in mice and accounts for erythrocyte hypoxic memory and faster acclimatization. Our findings suggest that targeting identified purinergic-signalling network would enhance the hypoxia adenosine response to counteract hypoxia-induced maladaptation. Humans that reach high altitude soon after the first ascent show faster adaptation to hypoxia. Song et al. show that this adaptive response relies on decreased red blood cell uptake of plasma adenosine due to reduced levels of nucleoside transporter ENT1 resulting from coordinated adenosine generation by ectonucleotidase CD73 and activation of A2B receptors.
Collapse
Affiliation(s)
- Anren Song
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Yujin Zhang
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Leng Han
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | | | - Hong Liu
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Kaiqi Sun
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Angelo D'Alessandro
- Department of Biochemistry and Molecular Genetics, University of Colorado, Aurora, Colorado 80045, USA
| | - Jessica Li
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Harry Karmouty-Quintana
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Takayuki Iriyama
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Tingting Weng
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Shushan Zhao
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 410008 Hunan, China
| | - Wei Wang
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Department of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008 Hunan, China
| | - Hongyu Wu
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Travis Nemkov
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Andrew W Subudhi
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Sonja Jameson-Van Houten
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Colleen G Julian
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Andrew T Lovering
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Kirk C Hansen
- Department of Biochemistry and Molecular Genetics, University of Colorado, Aurora, Colorado 80045, USA
| | - Hong Zhang
- Department of Pathology, MD Anderson Cancer Center, Houston, Texas 77030, USA
| | - Mikhail Bogdanov
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - William Dowhan
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Jianping Jin
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Rodney E Kellems
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Holger K Eltzschig
- Organ Protection Program, Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Michael Blackburn
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
| | - Robert C Roach
- Altitude Research Center, Department of Emergency Medicine University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Yang Xia
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.,Department of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008 Hunan, China
| |
Collapse
|
16
|
Liu H, Zhang Y, Wu H, D'Alessandro A, Yegutkin GG, Song A, Sun K, Li J, Cheng NY, Huang A, Edward Wen Y, Weng TT, Luo F, Nemkov T, Sun H, Kellems RE, Karmouty-Quintana H, Hansen KC, Zhao B, Subudhi AW, Jameson-Van Houten S, Julian CG, Lovering AT, Eltzschig HK, Blackburn MR, Roach RC, Xia Y. Beneficial Role of Erythrocyte Adenosine A2B Receptor-Mediated AMP-Activated Protein Kinase Activation in High-Altitude Hypoxia. Circulation 2016; 134:405-21. [PMID: 27482003 DOI: 10.1161/circulationaha.116.021311] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 06/14/2016] [Indexed: 12/18/2022]
Abstract
BACKGROUND High altitude is a challenging condition caused by insufficient oxygen supply. Inability to adjust to hypoxia may lead to pulmonary edema, stroke, cardiovascular dysfunction, and even death. Thus, understanding the molecular basis of adaptation to high altitude may reveal novel therapeutics to counteract the detrimental consequences of hypoxia. METHODS Using high-throughput, unbiased metabolomic profiling, we report that the metabolic pathway responsible for production of erythrocyte 2,3-bisphosphoglycerate (2,3-BPG), a negative allosteric regulator of hemoglobin-O2 binding affinity, was significantly induced in 21 healthy humans within 2 hours of arrival at 5260 m and further increased after 16 days at 5260 m. RESULTS This finding led us to discover that plasma adenosine concentrations and soluble CD73 activity rapidly increased at high altitude and were associated with elevated erythrocyte 2,3-BPG levels and O2 releasing capacity. Mouse genetic studies demonstrated that elevated CD73 contributed to hypoxia-induced adenosine accumulation and that elevated adenosine-mediated erythrocyte A2B adenosine receptor activation was beneficial by inducing 2,3-BPG production and triggering O2 release to prevent multiple tissue hypoxia, inflammation, and pulmonary vascular leakage. Mechanistically, we demonstrated that erythrocyte AMP-activated protein kinase was activated in humans at high altitude and that AMP-activated protein kinase is a key protein functioning downstream of the A2B adenosine receptor, phosphorylating and activating BPG mutase and thus inducing 2,3-BPG production and O2 release from erythrocytes. Significantly, preclinical studies demonstrated that activation of AMP-activated protein kinase enhanced BPG mutase activation, 2,3-BPG production, and O2 release capacity in CD73-deficient mice, in erythrocyte-specific A2B adenosine receptor knockouts, and in wild-type mice and in turn reduced tissue hypoxia and inflammation. CONCLUSIONS Together, human and mouse studies reveal novel mechanisms of hypoxia adaptation and potential therapeutic approaches for counteracting hypoxia-induced tissue damage.
Collapse
Affiliation(s)
- Hong Liu
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Yujin Zhang
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Hongyu Wu
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Angelo D'Alessandro
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Gennady G Yegutkin
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Anren Song
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Kaiqi Sun
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Jessica Li
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Ning-Yuan Cheng
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Aji Huang
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Yuan Edward Wen
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Ting Ting Weng
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Fayong Luo
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Travis Nemkov
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Hong Sun
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Rodney E Kellems
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Harry Karmouty-Quintana
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Kirk C Hansen
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Bihong Zhao
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Andrew W Subudhi
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Sonja Jameson-Van Houten
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Colleen G Julian
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Andrew T Lovering
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Holger K Eltzschig
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Michael R Blackburn
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Robert C Roach
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.)
| | - Yang Xia
- From the Department of Biochemistry and Molecular Biology (H.L., Y.Z., H.W., A.S., K.S., J.L., N.-Y.C., A.H., Y.E.W., T.T.W., F.L., R.E.K., H.K.-Q., M.R.B., Y.X.), Graduate School of Biomedical Sciences (H.L., K.S., R.E.K., M.R.B., Y.X.), and Department of Pathology (B.Z.), University of Texas Health Science Center at Houston; Departments of Otolaryngology (H.L., H.S.) and Nephrology (Y.X.), Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora (A.D., T.N., K.C.H.); Medicity Research Laboratory, University of Turku, Turku, Finland (G.G.Y.); Altitude Research Center, Department of Emergency Medicine (A.W.S., S.J.-V.H., C.G.J., R.C.R.), and Organ Protection Program, Department of Anesthesiology (H.K.E.), University of Colorado School of Medicine, Aurora; and Department of Human Physiology, University of Oregon, Eugene (A.TL.).
| |
Collapse
|
17
|
Yegutkin GG, Guerrero-Toro C, Kilinc E, Koroleva K, Ishchenko Y, Abushik P, Giniatullina R, Fayuk D, Giniatullin R. Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions. Purinergic Signal 2016; 12:561-74. [PMID: 27369815 DOI: 10.1007/s11302-016-9521-8] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 06/23/2016] [Indexed: 11/26/2022] Open
Abstract
Extracellular ATP is suspected to contribute to migraine pain but regulatory mechanisms controlling pro-nociceptive purinergic mechanisms in the meninges remain unknown. We studied the peculiarities of metabolic and signaling pathways of ATP and its downstream metabolites in rat meninges and in cultured trigeminal cells exposed to the migraine mediator calcitonin gene-related peptide (CGRP). Under resting conditions, meningeal ATP and ADP remained at low nanomolar levels, whereas extracellular AMP and adenosine concentrations were one-two orders higher. CGRP increased ATP and ADP levels in meninges and trigeminal cultures and reduced adenosine concentration in trigeminal cells. Degradation rates for exogenous nucleotides remained similar in control and CGRP-treated meninges, indicating that CGRP triggers nucleotide release without affecting nucleotide-inactivating pathways. Lead nitrate-based enzyme histochemistry of whole mount meninges revealed the presence of high ATPase, ADPase, and AMPase activities, primarily localized in the medial meningeal artery. ATP and ADP induced large intracellular Ca(2+) transients both in neurons and in glial cells whereas AMP and adenosine were ineffective. In trigeminal glia, ATP partially operated via P2X7 receptors. ATP, but not other nucleotides, activated nociceptive spikes in meningeal trigeminal nerve fibers providing a rationale for high degradation rate of pro-nociceptive ATP. Pro-nociceptive effect of ATP in meningeal nerves was reproduced by α,β-meATP operating via P2X3 receptors. Collectively, extracellular ATP, which level is controlled by CGRP, can persistently activate trigeminal nerves in meninges which considered as the origin site of migraine headache. These data are consistent with the purinergic hypothesis of migraine pain and suggest new targets against trigeminal pain.
Collapse
Affiliation(s)
| | - Cindy Guerrero-Toro
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
| | - Erkan Kilinc
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
- Department of Physiology, Medical Faculty, Abant Izzet Baysal University, Bolu, Turkey
| | - Kseniya Koroleva
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
- Kazan Federal University, Kazan, Russia
| | - Yevheniia Ishchenko
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
| | - Polina Abushik
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
| | - Raisa Giniatullina
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
| | - Dmitriy Fayuk
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland
| | - Rashid Giniatullin
- Department of Neurobiology, A.I.Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulaniementie 2, P.O. Box 1627, 70211, Kuopio, Finland.
- Kazan Federal University, Kazan, Russia.
| |
Collapse
|
18
|
Abstract
In recent years, cancer immunotherapy made significant advances due to a better understanding of the principles underlying tumor biology and immunology. In this context, CD73 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tumor microenvironment that promotes the onset and progression of cancer. Targeting CD73 results in favorable antitumor effects in pre-clinical models and combined treatments of CD73 blockade with other immune-modulating agents (i.e. anti-CTLA-4 mAb or anti-PD1 mAb) is particularly attractive. Although there is still a long way to go, anti-CD73 therapy, through the development of CD73 monoclonal antibodies, can potentially constitute a new biologic therapy for cancer patients. In this review, we discuss the link between CD73 and the onset, development and spread of tumors, highlighting the potential value of this molecule as a target and as a novel biomarker in the context of personalized cancer therapy.
Collapse
Affiliation(s)
- Luca Antonioli
- Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| | - Gennady G Yegutkin
- Medicity Research Laboratory, Department of Medical Microbiology and Immunology, University of Turku, Finland
| | - Pál Pacher
- Section on Oxidative Stress Tissue Injury, Laboratories of Physiological Studies, National Institutes of Health/NIAAA, Bethesda, MD 20892, USA
| | - Corrado Blandizzi
- Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
| | - György Haskó
- Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
| |
Collapse
|
19
|
Lazar Z, Müllner N, Lucattelli M, Ayata CK, Cicko S, Yegutkin GG, De Cunto G, Müller T, Meyer A, Hossfeld M, Sorichter S, Horvath I, Virchow CJ, Robson SC, Lungarella G, Idzko M. NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD. Eur Respir J 2016; 47:254-63. [PMID: 26541524 DOI: 10.1183/13993003.02144-2014] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 08/05/2015] [Indexed: 01/06/2023]
Abstract
Purinergic receptor activation via extracellular ATP is involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). Nucleoside triphosphate diphosphohydrolase-1/CD39 hydrolyses extracellular ATP and modulates P2 receptor signalling.We aimed to investigate the expression and function of CD39 in the pathogenesis of cigarette smoke-induced lung inflammation in patients and preclinical mouse models. CD39 expression and soluble ATPase activity were quantified in sputum and bronchoalveolar lavage fluid (BALF) cells in nonsmokers, smokers and COPD patients or mice with cigarette smoke-induced lung inflammation. In mice, pulmonary ATP and cytokine concentrations, inflammation and emphysema were analysed in the presence or absence of CD39.Following acute cigarette smoke exposure CD39 was upregulated in BALF cells in smokers with further increases in COPD patients. Acute cigarette smoke exposure induced CD39 upregulation in murine lungs and BALF cells, and ATP degradation was accelerated in airway fluids. CD39 inhibition and deficiency led to augmented lung inflammation; treatment with ATPase during cigarette smoke exposure prevented emphysema.Pulmonary CD39 expression and activity are increased in COPD. CD39 deficiency leads to enhanced emphysema in mice, while external administration of a functional CD39 analogue partially rescues the phenotype. The compensatory upregulation of pulmonary CD39 might serve as a protective mechanism in cigarette smoke-induced lung damage.
Collapse
Affiliation(s)
- Zsofia Lazar
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany Dept of Pulmonology, Semmelweis University, Budapest, Hungary These authors contributed equally
| | - Nina Müllner
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany These authors contributed equally
| | - Monica Lucattelli
- Dept of Life Sciences, University of Siena, Siena, Italy These authors contributed equally
| | - Cemil Korcan Ayata
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany These authors contributed equally
| | - Sanja Cicko
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| | | | | | - Tobias Müller
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| | - Anja Meyer
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| | - Madelon Hossfeld
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| | - Stephan Sorichter
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| | - Ildiko Horvath
- Dept of Pulmonology, Semmelweis University, Budapest, Hungary
| | | | - Simon C Robson
- Division of Gastroenterology, Dept of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | | | - Marco Idzko
- Dept of Pulmonology, University Hospital Freiburg, Freiburg, Germany
| |
Collapse
|
20
|
Yegutkin GG. Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit Rev Biochem Mol Biol 2015; 49:473-97. [PMID: 25418535 DOI: 10.3109/10409238.2014.953627] [Citation(s) in RCA: 215] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Extracellular nucleotides and nucleosides mediate diverse signaling effects in virtually all organs and tissues. Most models of purinergic signaling depend on functional interactions between distinct processes, including (i) the release of endogenous ATP and other nucleotides, (ii) triggering of signaling events via a series of nucleotide-selective ligand-gated P2X and metabotropic P2Y receptors as well as adenosine receptors and (iii) ectoenzymatic interconversion of purinergic agonists. The duration and magnitude of purinergic signaling is governed by a network of ectoenzymes, including the enzymes of the nucleoside triphosphate diphosphohydrolase (NTPDase) family, the nucleotide pyrophosphatase/phosphodiesterase (NPP) family, ecto-5'-nucleotidase/CD73, tissue-nonspecific alkaline phosphatase (TNAP), prostatic acid phosphatase (PAP) and other alkaline and acid phosphatases, adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP). Along with "classical" inactivating ectoenzymes, recent data provide evidence for the co-existence of a counteracting ATP-regenerating pathway comprising the enzymes of the adenylate kinase (AK) and nucleoside diphosphate kinase (NDPK/NME/NM23) families and ATP synthase. This review describes recent advances in this field, with special emphasis on purine-converting ectoenzymes as a complex and integrated network regulating purinergic signaling in such (patho)physiological states as immunomodulation, inflammation, tumorigenesis, arterial calcification and other diseases. The second part of this review provides a comprehensive overview and basic principles of major approaches employed for studying purinergic activities, including spectrophotometric Pi-liberating assays, high-performance liquid chromatographic (HPLC) and thin-layer chromatographic (TLC) analyses of purine substrates and metabolites, capillary electrophoresis, bioluminescent, fluorometric and electrochemical enzyme-coupled assays, histochemical staining, and further emphasizes their advantages, drawbacks and suitability for assaying a particular catalytic reaction.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- Department of Medical Microbiology and Immunology, University of Turku , Turku , Finland
| |
Collapse
|
21
|
Bhattarai S, Freundlieb M, Pippel J, Meyer A, Abdelrahman A, Fiene A, Lee SY, Zimmermann H, Yegutkin GG, Sträter N, El-Tayeb A, Müller CE. α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5'-Nucleotidase (CD73) Inhibitors. J Med Chem 2015; 58:6248-63. [PMID: 26147331 DOI: 10.1021/acs.jmedchem.5b00802] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
ecto-5'-Nucleotidase (eN, CD73) catalyzes the hydrolysis of extracellular AMP to adenosine. eN inhibitors have potential for use as cancer therapeutics. The eN inhibitor α,β-methylene-ADP (AOPCP, adenosine-5'-O-[(phosphonomethyl)phosphonic acid]) was used as a lead structure, and derivatives modified in various positions were prepared. Products were tested at rat recombinant eN. 6-(Ar)alkylamino substitution led to the largest improvement in potency. N(6)-Monosubstitution was superior to symmetrical N(6),N(6)-disubstitution. The most potent inhibitors were N(6)-(4-chlorobenzyl)- (10l, PSB-12441, Ki 7.23 nM), N(6)-phenylethyl- (10h, PSB-12425, Ki 8.04 nM), and N(6)-benzyl-adenosine-5'-O-[(phosphonomethyl)phosphonic acid] (10g, PSB-12379, Ki 9.03 nM). Replacement of the 6-NH group in 10g by O (10q, PSB-12431) or S (10r, PSB-12553) yielded equally potent inhibitors (10q, 9.20 nM; 10r, 9.50 nM). Selected compounds investigated at the human enzyme did not show species differences; they displayed high selectivity versus other ecto-nucleotidases and ADP-activated P2Y receptors. Moreover, high metabolic stability was observed. These compounds represent the most potent eN inhibitors described to date.
Collapse
Affiliation(s)
- Sanjay Bhattarai
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Marianne Freundlieb
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Jan Pippel
- ‡Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, University of Leipzig, Deutscher Platz 5, D-04103 Leipzig, Germany
| | - Anne Meyer
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Aliaa Abdelrahman
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Amelie Fiene
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Sang-Yong Lee
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Herbert Zimmermann
- §Institute of Cell Biology and Neuroscience, Goethe-University, D-60438 Frankfurt am Main, Germany
| | - Gennady G Yegutkin
- ∥MediCity Research Laboratory, University of Turku, 20520 Turku, Finland
| | - Norbert Sträter
- ‡Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, University of Leipzig, Deutscher Platz 5, D-04103 Leipzig, Germany
| | - Ali El-Tayeb
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| | - Christa E Müller
- †PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
| |
Collapse
|
22
|
Jalkanen J, Yegutkin GG, Hollmén M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circ Res 2015; 116:1206-15. [PMID: 25645301 DOI: 10.1161/circresaha.116.305715] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
RATIONALE Purinergic signaling plays an important role in inflammation and vascular integrity, but little is known about purinergic mechanisms during the pathogenesis of atherosclerosis in humans. OBJECTIVE The objective of this study is to study markers of purinergic signaling in a cohort of patients with peripheral artery disease. METHODS AND RESULTS Plasma ATP and ADP levels and serum nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasive imaging and treatment. The major findings were that ATP, ADP, and CD73 values were higher in atherosclerotic patients than in controls without clinically evident peripheral artery disease (P<0.0001). Low CD39 activity was associated with disease progression (P=0.01). In multivariable linear regression models, high CD73 activity was associated with chronic hypoxia (P=0.001). Statin use was associated with lower ADP (P=0.041) and tended to associate with higher CD73 (P=0.054), while lower ATP was associated with the use of angiotensin receptor blockers (P=0.015). CONCLUSIONS Purinergic signaling plays an important role in peripheral artery disease progression. Elevated levels of circulating ATP and ADP are especially associated with atherosclerotic diseases of younger age and smoking. The antithrombotic and anti-inflammatory effects of statins may partly be explained by their ability to lower ADP. We suggest that the prothrombotic nature of smoking could be a cause of elevated ADP, and this may explain why cardiovascular patients who smoke benefit from platelet P2Y12 receptor antagonists more than their nonsmoking peers.
Collapse
Affiliation(s)
- Juho Jalkanen
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Gennady G Yegutkin
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Maija Hollmén
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Kristiina Aalto
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Tuomas Kiviniemi
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Veikko Salomaa
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| | - Sirpa Jalkanen
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.).
| | - Harri Hakovirta
- From the Department of Vascular Surgery (J.J., H.H.) and Heart Center (T.K.), Turku University Hospital, Turku, Finland; Medicity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland (G.G.Y., M.H., K.A., S.J.); and National Institute for Health and Welfare, Helsinki, Finland (V.S.)
| |
Collapse
|
23
|
Loukovaara S, Sahanne S, Jalkanen S, Yegutkin GG. Increased intravitreal adenosine 5'-triphosphate, adenosine 5'-diphosphate and adenosine 5'-monophosphate levels in patients with proliferative diabetic retinopathy. Acta Ophthalmol 2015; 93:67-73. [PMID: 25079888 DOI: 10.1111/aos.12507] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 06/04/2014] [Indexed: 12/28/2022]
Abstract
PURPOSE Extracellular purines play important role in ocular physiology, diabetes, vascular remodelling and adaptation to inflammation. This study was aimed to evaluate intravitreal purine levels in patients with diabetic retinopathy (DR) and other non-vascular vitreoretinal eye diseases. METHODS Vitreous samples were collected at the start of the three-port pars plana vitrectomy. Study group comprised 55 eyes operated due to sight-threatening forms of DR, including eyes of 24 patients with proliferative DR. Of the 143 non-diabetic controls, 112 had rhegmatogenous retinal detachment and 31 macular hole or pucker. Intravitreal purine concentrations were determined using a combination of bioluminescent [adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP)] and fluorometric [adenosine 5'-monophosphate (AMP), adenosine, inosine] enzyme-coupled sensing assays. RESULTS Compared with non-diabetic controls, DR eyes contained significantly higher (p < 0.01) concentrations of ATP (4.2 ± 0.6 versus 34.5 ± 13.7 nm; mean ± SEM), ADP (19.5 ± 2.7 versus 43.7 ± 14.5 nm) and AMP (1290 ± 115 versus 1876 ± 190 nm). Intravitreal adenosine and inosine levels varied within submicromolar to low micromolar range, and their concentrations did not differ between the groups studied. CONCLUSIONS High concentrations of intravitreal nucleotides ATP, ADP and AMP may be related to the pathogenesis of sight-threatening forms of DR.
Collapse
Affiliation(s)
- Sirpa Loukovaara
- Unit of Vitreoretinal Surgery; Department of Ophthalmology; Helsinki University Central Hospital; Helsinki Finland
| | - Sari Sahanne
- Unit of Anesthesiology and Intensive Care Medicine; Eye-ENT Hospital; Helsinki University Central Hospital; Helsinki Finland
| | - Sirpa Jalkanen
- MediCity Research Laboratory; University of Turku and Turku University Hospital; Turku Finland
- National Institute for Health and Welfare; Turku Finland
| | - Gennady G. Yegutkin
- MediCity Research Laboratory; University of Turku and Turku University Hospital; Turku Finland
- National Institute for Health and Welfare; Turku Finland
| |
Collapse
|
24
|
Yegutkin GG, Auvinen K, Rantakari P, Hollmén M, Karikoski M, Grénman R, Elima K, Jalkanen S, Salmi M. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. Eur J Immunol 2014; 45:562-73. [PMID: 25402681 DOI: 10.1002/eji.201444856] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Revised: 09/22/2014] [Accepted: 11/10/2014] [Indexed: 12/20/2022]
Abstract
CD73/ecto-5'-nucleotidase is a key enzyme in the regulation of purinergic signaling and inflammatory reactions. It hydrolyzes extracellular AMP into adenosine, which dampens immune cell activation, and reduces leukocyte trafficking. By comparing CD73 expression and function in mononuclear and endothelial cells (ECs) of blood and lymph, we show that extracellular purines and CD73 activity have differential effects in these two vascular systems. We found that CD8-positive T lymphocytes and CD19-positive B lymphocytes in human lymph expressed high levels of CD73 and other purinergic enzymes and adenosine receptors. Soluble CD73 was less abundant in human lymph than in serum, whereas CD73 activity was higher in afferent lymphatic ECs than in blood ECs. Adenosine signaling improved barrier function and induced sprouting of human blood, but not lymphatic, ECs in vitro. Similarly, using CD73-deficient mice we found that CD73 controls only blood vascular permeability at selected lymphoid organs under physiological conditions. Thus, both vascular and lymphatic arms of the immune system synthesize the components of purinergic signaling system, but surprisingly they use CD73 differentially to control endothelial permeability and sprouting.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- Medicity Research Laboratory, University of Turku, Turku, Finland; Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Gnad T, Scheibler S, von Kügelgen I, Scheele C, Kilić A, Glöde A, Hoffmann LS, Reverte-Salisa L, Horn P, Mutlu S, El-Tayeb A, Kranz M, Deuther-Conrad W, Brust P, Lidell ME, Betz MJ, Enerbäck S, Schrader J, Yegutkin GG, Müller CE, Pfeifer A. Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors. Nature 2014; 516:395-9. [DOI: 10.1038/nature13816] [Citation(s) in RCA: 263] [Impact Index Per Article: 26.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Accepted: 09/01/2014] [Indexed: 02/06/2023]
|
26
|
Virtanen SS, Kukkonen-Macchi A, Vainio M, Elima K, Härkönen PL, Jalkanen S, Yegutkin GG. Adenosine inhibits tumor cell invasion via receptor-independent mechanisms. Mol Cancer Res 2014; 12:1863-74. [PMID: 25080434 DOI: 10.1158/1541-7786.mcr-14-0302-t] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED Extracellular adenosine mediates diverse anti-inflammatory, angiogenic, and other signaling effects via binding to adenosine receptors, and it also regulates cell proliferation and death via activation of the intrinsic signaling pathways. Given the emerging role of adenosine and other purines in tumor growth and metastasis, this study evaluated the effects of adenosine on the invasion of metastatic prostate and breast cancer cells. Treatment with low micromolar concentrations of adenosine, but not other nucleosides or adenosine receptor agonists, inhibited subsequent cell invasion and migration through Matrigel- and laminin-coated inserts. These inhibitory effects occurred via intrinsic receptor-independent mechanisms, despite the abundant expression of A2B adenosine receptors (ADORA2B). Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5'-nucleotidase (CD73/NT5E) and adenosine deaminase reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP. This was accompanied by concurrent inhibition of AMP-activated protein kinase and other signaling pathways. No differences in the proliferation rates, cytoskeleton assembly, expression of major adhesion molecules [integrin-1β (ITGB1), CD44, focal adhesion kinase], and secretion of matrix metalloproteinases were detected between the control and treated cells, thus excluding the contribution of these components of invasion cascade to the inhibitory effects of adenosine. These data provide a novel insight into the ability of adenosine to dampen immune responses and prevent tumor invasion via two different, adenosine receptor-dependent and -independent mechanisms. IMPLICATIONS This study suggests that the combined targeting of adenosine receptors and modulation of intracellular purine levels can affect tumor growth and metastasis phenotypes.
Collapse
Affiliation(s)
- Sanna S Virtanen
- Turku University of Applied Sciences, University of Turku, Turku, Finland. Department of Cell Biology and Anatomy, University of Turku, Turku, Finland
| | | | - Minna Vainio
- Department of Biology, University of Turku, Turku, Finland
| | - Kati Elima
- Department of Medical Microbiology, University of Turku, Turku, Finland
| | - Pirkko L Härkönen
- Department of Cell Biology and Anatomy, University of Turku, Turku, Finland
| | - Sirpa Jalkanen
- Department of Medical Microbiology, University of Turku, Turku, Finland
| | - Gennady G Yegutkin
- Department of Medical Microbiology, University of Turku, Turku, Finland.
| |
Collapse
|
27
|
Bellingan G, Maksimow M, Howell DC, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, Shah S, Cooper J, Waris M, Yegutkin GG, Jalkanen J, Salmi M, Piippo I, Jalkanen M, Montgomery H, Jalkanen S. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2013; 2:98-107. [PMID: 24503265 DOI: 10.1016/s2213-2600(13)70259-5] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Pulmonary vascular leakage occurs early in acute respiratory distress syndrome (ARDS). Mortality is high (35-45%), but no effective pharmacotherapy exists. Production of anti-inflammatory adenosine by ecto-5'-nucleotidase (CD73) helps maintain endothelial barrier function. We tested whether interferon-beta-1a (IFN-beta-1a), which increases CD73 synthesis, can reduce vascular leakage and mortality in patients with ARDS. METHODS In ex-vivo studies, we first established that IFN-beta-1a induced CD73 up-regulation in cultured human lung tissue samples. We then tested the safety, tolerability, and efficacy of intravenous human recombinant IFN-beta-1a (FP-1201) in patients with ARDS in an open-label study (comprising dose-escalation and expansion phases). We recruited patients from eight intensive care units in the UK. Eligible patients were aged 18 years or older, had ARDS, and were being treated with assisted ventilation. We established an optimal tolerated dose (OTD) in the first, dose-escalation phase. Once established, we gave all subsequently enrolled patients the OTD of intravenous FP-1201 for 6 days. We assessed 28-day mortality (our primary endpoint) in all patients receiving the OTD versus 28-day mortality in a group of patients who did not receive treatment (this control group comprised patients in the study but who did not receive treatment because they were screened during the safety windows after dose escalation). This trial is registered with ClinicalTrials.gov, number NCT00789685, and the EU Clinical Trials Register EudraCT, number 2008-000140-13. FINDINGS IFN-beta-1a increased the number of CD73-positive vessels in lung culture by four times on day 1 (p=0·04) and by 14·3 times by day 4 (p=0·004). For the clinical trial, between Feb 23, 2009, and April 7, 2011, we identified 150 patients, of whom 37 were enrolled into the trial and given treatment. The control group consisted of 59 patients who were recruited to take part in the study, but who did not receive treatment. Demographic characteristics and severity of illness did not differ between treatment and control groups. The optimal tolerated FP-1201 dose was 10 μg per day for 6 days. By day 28, 3 (8%) of 37 patients in the treatment cohort and 19 (32%) of 59 patients in the control cohort had died-thus, treatment with FP-1201 was associated with an 81% reduction in odds of 28-day mortality (odds ratio 0·19 [95% CI 0·03-0·72]; p=0·01). INTERPRETATION FP-1201 up-regulates human lung CD73 expression, and is associated with a reduction in 28-day mortality in patients with ARDS. Our findings need to be substantiated in large, prospective randomised trials, but suggest that FP-1201 could be the first effective, mechanistically targeted, disease-specific pharmacotherapy for patients with ARDS.
Collapse
Affiliation(s)
- Geoff Bellingan
- Critical Care, University College Hospital, London, UK; Department of Medicine, University College London and NIHR University College London Hospitals Biomedical Research Centre, UK
| | | | | | | | | | | | | | | | | | | | | | - Jackie Cooper
- Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, UK
| | - Matti Waris
- Department of Virology, University of Turku, Finland
| | - Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, Finland; Department of Medical Microbiology, University of Turku, Finland
| | - Juho Jalkanen
- Department of Vascular Surgery, Turku University Hospital, Finland
| | - Marko Salmi
- MediCity Research Laboratory, University of Turku, Finland; Department of Medical Biochemistry and Genetics, University of Turku, Finland
| | | | | | - Hugh Montgomery
- Department of Medicine, University College London and NIHR University College London Hospitals Biomedical Research Centre, UK; Whittington Hospital London, UK
| | - Sirpa Jalkanen
- MediCity Research Laboratory, University of Turku, Finland; Department of Medical Microbiology, University of Turku, Finland.
| |
Collapse
|
28
|
Kulesskaya N, Võikar V, Peltola M, Yegutkin GG, Salmi M, Jalkanen S, Rauvala H. CD73 is a major regulator of adenosinergic signalling in mouse brain. PLoS One 2013; 8:e66896. [PMID: 23776700 PMCID: PMC3680420 DOI: 10.1371/journal.pone.0066896] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2013] [Accepted: 05/13/2013] [Indexed: 12/20/2022] Open
Abstract
CD73 (ecto-5'-nucleotidase) is a cell surface enzyme that regulates purinergic signalling by desphosphorylating extracellular AMP to adenosine. 5'-nucleotidases are known to be expressed in brain, but the expression of CD73 and its putative physiological functions at this location remain elusive. Here we found, using immunohistochemistry of wild-type and CD73 deficient mice, that CD73 is prominently expressed in the basal ganglia core comprised of striatum (caudate nucleus and putamen) and globus pallidus. Furthermore, meninges and the olfactory tubercle were found to specifically express CD73. Analysis of wild type (wt) and CD73 deficient mice revealed that CD73 confers the majority of 5'-nucleotidase activity in several areas of the brain. In a battery of behavioural tests and in IntelliCage studies, the CD73 deficient mice demonstrated significantly enhanced exploratory locomotor activity, which probably reflects the prominent expression of CD73 in striatum and globus pallidus that are known to control locomotion. Furthermore, the CD73 deficient mice displayed altered social behaviour. Overall, our data provide a novel mechanistic insight into adenosinergic signalling in brain, which is implicated in the regulation of normal and pathological behaviour.
Collapse
Affiliation(s)
- Natalia Kulesskaya
- Neuroscience Center, University of Helsinki, Helsinki, Finland
- Department of Biosciences, University of Helsinki, Helsinki, Finland
| | - Vootele Võikar
- Neuroscience Center, University of Helsinki, Helsinki, Finland
- Department of Biosciences, University of Helsinki, Helsinki, Finland
- * E-mail: (VV); (HR)
| | | | - Gennady G. Yegutkin
- MediCity and Department of Medical Microbiology and Immunology, University of Turku and National Institute of Health and Welfare, Turku, Finland
| | - Marko Salmi
- MediCity and Department of Medical Microbiology and Immunology, University of Turku and National Institute of Health and Welfare, Turku, Finland
- Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland
| | - Sirpa Jalkanen
- MediCity and Department of Medical Microbiology and Immunology, University of Turku and National Institute of Health and Welfare, Turku, Finland
| | - Heikki Rauvala
- Neuroscience Center, University of Helsinki, Helsinki, Finland
- * E-mail: (VV); (HR)
| |
Collapse
|
29
|
Kiviniemi TO, Yegutkin GG, Toikka JO, Paul S, Aittokallio T, Janatuinen T, Knuuti J, Rönnemaa T, Koskenvuo JW, Hartiala JJ, Jalkanen S, Raitakari OT. Pravastatin-induced improvement in coronary reactivity and circulating ATP and ADP levels in young adults with type 1 diabetes. Front Physiol 2012; 3:338. [PMID: 22934084 PMCID: PMC3429103 DOI: 10.3389/fphys.2012.00338] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 08/01/2012] [Indexed: 12/20/2022] Open
Abstract
Aims: Extracellular ATP and ADP regulate diverse inflammatory, prothrombotic and vasoactive responses in the vasculature. Statins have been shown to modulate their signaling pathways in vitro. We hypothesized that altered intravascular nucleotide turnover modulates vasodilation in patients with type 1 diabetes (T1DM), and this can be partly restored with pravastatin therapy. Methods: In this randomized double blind study, plasma ATP and ADP levels and echocardiography-derived coronary flow velocity response to cold pressor test (CPT) were concurrently assessed in 42 normocholesterolemic patients with T1DM (age 30 ± 6 years, LDL cholesterol 2.5 ± 0.6 mmol/L) before and after four-month treatment with pravastatin 40 mg/day or placebo (n = 22 and n = 20, respectively), and in 41 healthy control subjects. Results: Compared to controls, T1DM patients had significantly higher concentrations of ATP (p < 0.01) and ADP (p < 0.01) and these levels were partly restored after treatment with pravastatin (p = 0.002 and p = 0.007, respectively), but not after placebo (p = 0.06 and p = 0.14, respectively). Coronary flow velocity acceleration was significantly lower in T1DM patients compared to control subjects, and it increased from pre- to post-intervention in the pravastatin (p = 0.02), but not in placebo group (p = 0.15). Conclusions: Pravastatin treatment significantly reduces circulating ATP and ADP levels of T1DM patients, and concurrently improves coronary flow response to CPT. This study provides a novel insight in purinergic mechanisms involved in pleiotropic effects of pravastatin.
Collapse
Affiliation(s)
- Tuomas O Kiviniemi
- Department of Clinical Physiology, Turku University Hospital Turku, Finland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Yegutkin GG, Wieringa B, Robson SC, Jalkanen S. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities. FASEB J 2012; 26:3875-83. [PMID: 22637533 DOI: 10.1096/fj.12-205658] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Extracellular ATP and ADP trigger inflammatory, vasodilatatory, and prothrombotic signaling events in the vasculature, and their turnover is governed by networks of membrane-associated enzymes. The contribution of soluble activities to intravascular nucleotide homeostasis remains controversial. By using thin-layer chromatographic assays, we revealed transphosphorylation of [γ-(32)P]ATP and AMP by human and murine sera, which was progressively inhibited by specific adenylate kinase (AK) inhibitor Ap(5)A. This phosphotransfer reaction was diminished markedly in serum from knockout mice lacking the major AK isoform, AK1, and in human serum immunodepleted of AK1. We also showed that ∼75% ADP in cell-free serum is metabolized via reversible AK1 reaction 2ADP ↔ ATP + AMP. The generated ATP and AMP are then metabolized through the coupled nucleotide pyrophosphatase/phosphodiesterase and 5'-nucleotidase/CD73 reactions, respectively. Constitutive presence of another nucleotide-converting enzyme, nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, known as CD39), was ascertained by the relative deficiency of serum from CD39-null mice to dephosphorylate [(3)H]ADP and [γ-(32)P]ATP, and also by diminished [(3)H]ADP hydrolysis by human serum pretreated with NTPDase1 inhibitors, POM-1 and ARL-67156. In summary, we have identified hitherto unrecognized soluble forms of AK1 and NTPDase1/CD39 that contribute in the active cycling between the principal platelet-recruiting agent ADP and other circulating nucleotides.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520 Turku, Finland.
| | | | | | | |
Collapse
|
31
|
Mercier N, Kiviniemi TO, Saraste A, Miiluniemi M, Silvola J, Jalkanen S, Yegutkin GG. Impaired ATP-induced coronary blood flow and diminished aortic NTPDase activity precede lesion formation in apolipoprotein E-deficient mice. Am J Pathol 2011; 180:419-28. [PMID: 22074736 DOI: 10.1016/j.ajpath.2011.10.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2011] [Revised: 09/21/2011] [Accepted: 10/04/2011] [Indexed: 02/02/2023]
Abstract
Intravascular ATP and ADP are important regulators of vascular tone, thrombosis, inflammation, and angiogenesis. This study was undertaken to evaluate the contribution of purinergic signaling to disturbed vasodilation and vascular remodeling during atherosclerosis progression. We used apolipoprotein E-deficient (Apoe(-/-)) mice as an appropriate experimental model for atherosclerosis. Noninvasive transthoracic Doppler echocardiography imaging with adenosine, ATP, and other nucleotides and nonhydrolyzable P2 receptor agonists and antagonists suggests that ATP regulates coronary blood flow in mice through activation of P2Y (most likely, endothelial ATP/UTP-selective P2Y(2)) receptors, rather than via its dephosphorylation to adenosine. Strikingly, compared to age-matched wild-type controls, young (10- to 15-week-old) Apoe(-/-) mice displayed diminished coronary reactivity in response to ATP but not adenosine. The impaired hyperemic response to ATP persisted in older (20- to 30-week-old) Apoe(-/-) mice, which were additionally characterized by mild atherosclerosis (as ascertained by aortic Oil Red O staining) and a systemic increase in plasma ATP and ADP levels. Concurrent thin-layer chromatographic analysis of nucleoside triphosphate diphosphohydrolase (NTPDase) and ecto-5'-nucleotidase/CD73 activities in thoracic aortas, lymph nodes, spleen, and serum revealed that aortic NTPDase was decreased by 40% to 50% in a tissue-specific manner both in young and mature Apoe(-/-) mice. Collectively, disordered purinergic signaling in Apoe(-/-) mice may serve as important prerequisite for impaired blood flow, local accumulation of ATP and ADP at sites of atherogenesis, and eventually, the exacerbation of atherosclerosis.
Collapse
Affiliation(s)
- Nathalie Mercier
- Medicity Research Laboratory and the Department of Medical Microbiology, University of Turku, Turku, Finland
| | | | | | | | | | | | | |
Collapse
|
32
|
Yegutkin GG, Helenius M, Kaczmarek E, Burns N, Jalkanen S, Stenmark K, Gerasimovskaya EV. Chronic hypoxia impairs extracellular nucleotide metabolism and barrier function in pulmonary artery vasa vasorum endothelial cells. Angiogenesis 2011; 14:503-13. [PMID: 21922294 DOI: 10.1007/s10456-011-9234-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Accepted: 09/08/2011] [Indexed: 12/20/2022]
Abstract
Vascular remodeling plays a pivotal role in a variety of pathophysiological conditions where hypoxia and inflammation are prominent features. Intravascular ATP, ADP and adenosine are known as important regulators of vascular tone, permeability and homeostasis, however contribution of purinergic signalling to endothelial cell growth and angiogenesis remains poorly understood. By using vasa vasorum endothelial cells (VVEC) isolated from pulmonary artery adventitia of control and chronically hypoxic neonatal calves, these studies were aimed to evaluate the effect of hypoxia on biochemical and functional properties of microvascular endothelial network at the sites of angiogenesis. In comparison with normoxic controls, VVEC from hypoxic animals are characterized by (1) drastically impaired nucleoside triphosphate diphosphohydrolase-1 (NTPDase-1/CD39) and ecto-5'-nucleotidase/CD73 activities with respective increases in basal extracellular ATP and ADP levels (2) higher proliferative responses to low micromolar concentrations of ATP and ADP; and (3) enhanced permeability and disordered adenosinergic control of vascular barrier function (measured as a paracellular flux of 70 kDa fluorescein isothiocyanate-dextran). Together, these results suggest that unique pattern of purine-mediated angiogenic activation and enhanced leakiness of VVEC from chronically hypoxic vessels may be defined by disordered endothelial nucleotide homeostasis at sites of active neovascularization.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku and National Institute of Health and Welfare, Tykistökatu 6A, 20520, Turku, Finland.
| | | | | | | | | | | | | |
Collapse
|
33
|
Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemelä J, Laurila JP, Elima K, Jalkanen S, Salmi M. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41:1231-41. [PMID: 21469131 DOI: 10.1002/eji.201041292] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
CD73/ecto-5'-nucleotidase dephosphorylates extracellular AMP into adenosine, and it is a key enzyme in the regulation of adenosinergic signaling. The contribution of host CD73 to tumor growth and anti-tumor immunity has not been studied. Here, we show that under physiological conditions CD73-deficient mice had significantly elevated ATPase and ADPase activities in LN T cells. In a melanoma model, the growth of primary tumors and formation of metastasis were significantly attenuated in mice lacking CD73. Among tumor-infiltrating leukocytes there were fewer Tregs and mannose receptor-positive macrophages, and increased IFN-γ and NOS2 mRNA production in CD73-deficient mice. Treatment of tumor-bearing animals with soluble apyrase, an enzyme hydrolyzing ATP and ADP, significantly inhibited tumor growth and accumulation of intratumoral Tregs and mannose receptor-positive macrophages in the WT C57BL/6 mice but not in the CD73-deficient mice. Pharmacological inhibition of CD73 with α,β-methylene-adenosine-5'-diphosphate in WT mice retarded tumor progression similarly to the genetic deletion of CD73. Together these data show that increased pericellular ATP degradation in the absence of CD73 activity in the host cells is a novel mechanism controlling anti-tumor immunity and tumor progression, and that the purinergic balance can be manipulated therapeutically to inhibit tumor growth.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, and National Institute of Health and Welfare, Turku, Finland
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Yegutkin GG, Hytönen J, Samburski SS, Yrjänäinen H, Jalkanen S, Viljanen MK. Disordered lymphoid purine metabolism contributes to the pathogenesis of persistent Borrelia garinii infection in mice. J Immunol 2010; 184:5112-20. [PMID: 20357256 DOI: 10.4049/jimmunol.0902760] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Extracellular ATP and adenosine are important regulators of immune responses; however, contribution of purinergic signaling to host defense during persistent microbial infections remains obscure. Lyme borreliosis is a common arthropod-borne infection caused by Borrelia burgdorferi sensu lato. In this study, we investigated whether lymphoid purinergic signaling contributes to the mechanisms by which borreliae species evade the immune system and trigger joint inflammation. Intracutaneous inoculation of Borrelia garinii to C3H/He mice induced symptomatic infection manifested in elevated levels of borrelia-specific IgG Abs, persistent spirochete dissemination into the tissues and joint swelling, as well as approximately 2- to 2.5-fold enlargement of draining lymph nodes with hyperplasia of B cell follicle area and L-selectin shedding from activated T lymphocytes. Purine catabolism was also activated in lymph nodes but not spleen and blood of infected C3H/He mice within the first 4 postinfection weeks, particularly manifested in transient upregulations of adenosine triphosphatase/ectonucleoside triphosphate diphosphohydrolase and ecto-5'-nucleotidase/CD73 on CD4(+)CD8(+) T lymphocytes and adenosine deaminase activity on B220(+) B lymphocytes. Compared with borrelia-susceptible C3H/He strain, lymphocytes from C57BL/6 mice displayed markedly enhanced adenosine-generating capability due to approximately three times higher ratio of ecto-5'-nucleotidase to adenosine deaminase. Borrelia-infected C57BL/6 mice efficiently eradicated the inoculated spirochetes at more chronic stage without any signs of arthritis. Strikingly, deletion of key adenosine-generating enzyme, ecto-5'-nucleotidase/CD73, was accompanied by significantly enhanced joint swelling in borrelia-infected CD73-deficient C57BL/6 mice. Collectively, these data suggest that insufficient basal adenosine level and/or pathogen-induced disordered lymphoid purine homeostasis may serve as important prerequisite for promotion of inflammatory responses and further host's commitment to persistence of bacterial infection and arthritis development.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, Tykistökatu 6A, 20520 Turku, Finland.
| | | | | | | | | | | |
Collapse
|
35
|
Ujula T, Salomäki S, Virsu P, Lankinen P, Mäkinen TJ, Autio A, Yegutkin GG, Knuuti J, Jalkanen S, Roivainen A. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009; 36:631-41. [PMID: 19647169 DOI: 10.1016/j.nucmedbio.2009.04.008] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Revised: 03/18/2009] [Accepted: 04/06/2009] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Vascular adhesion protein-1 (VAP-1) is an infection/inflammation-inducible endothelial glycoprotein. Based on our previous studies, the most VAP-1-selective peptide (VAP-P1) was 1,4,7,10-tetraazacyclododecane-N',N'',N''',N-tetraacetic acid (DOTA)-conjugated, 68gallium (68Ga)-labeled (named [68Ga]DOTAVAP-P1) and evaluated preliminarily. METHODS Targeting was evaluated by using VAP-1-transfected cells. Biodistribution of [68Ga]DOTAVAP-P1 was studied by positron emission tomography imaging of healthy rats and rats with bone inflammation caused by Staphylococcus aureus infection. Uptake of [(68)Ga]DOTAVAP-P1 in osteomyelitis was compared with negative control peptide and competition with an excess of unlabeled DOTAVAP-P1. RESULTS [68Ga]DOTAVAP-P1 bound more efficiently to VAP-1-transfected cells than to controls. In rats, [68Ga]DOTAVAP-P1 cleared rapidly from blood circulation, excreted quickly in urine and showed an in vivo half-life of 26+/-2.3 min. Imaging of osteomyelitis demonstrated modest target-to-background ratio. Studies with the negative control peptide and competitors revealed a significantly lower uptake at the infection site compared to [68Ga]DOTAVAP-P1. CONCLUSIONS The results represent a proof-of-concept that infection-induced VAP-1 can be targeted by [68Ga]DOTA peptide. [68Ga]DOTAVAP-P1 is just the first candidate peptide and an essential opening for developing VAP-1-specific imaging agents.
Collapse
Affiliation(s)
- Tiina Ujula
- Turku PET Center, Turku University Hospital, Turku, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Niemelä J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, Airas L. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 2008; 38:2718-26. [PMID: 18825744 DOI: 10.1002/eji.200838437] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
IFN-beta treatment reduces the relapse rate in MS but its mechanism of action remains incompletely understood. Our aim was to clarify the beneficial effect of IFN-beta in the treatment of MS. We assessed the influence of IFN-beta treatment on (i) CD73 expression on the surface of primary cultures of human blood-brain barrier endothelial cells (BBB-EC) and human astrocytes using immunofluorescence staining and flow cytometry, (ii) transmigration of CD4+ T lymphocytes using an in vitro model of BBB and (iii) CD73 enzyme activity, i.e. ecto-5'-nucleotidase activity in the serum of MS patients using a radiochemical assay. IFN-beta increases the expression of ecto-5'-nucleotidase both on BBB-EC and astrocytes. As a consequence, lymphocyte transmigration through BBB-EC is reduced. Importantly, this reduction can be reversed using alpha,beta-methyleneadenosine-5'-diphosphate, a specific inhibitor of ecto-5'-nucleotidase. CD73 is strongly expressed in microvasculature in samples of postmortem MS brain and, moreover, in the majority of MS patients there was a clear upregulation both in the soluble serum ecto-5'-nucleotidase activity and skin microvascular CD73 expression after IFN-beta treatment. Upregulation of ecto-5'-nucleotidase and a subsequent increase in adenosine production might contribute to the beneficial effects of IFN-beta on MS via enhancing the endothelial barrier function.
Collapse
Affiliation(s)
- Jussi Niemelä
- Department of Medical Microbiology, MediCity Research Laboratory, University of Turku, Turku, Finland
| | | | | | | | | | | |
Collapse
|
37
|
Beldi G, Wu Y, Banz Y, Nowak M, Miller L, Enjyoji K, Haschemi A, Yegutkin GG, Candinas D, Exley M, Robson SC. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology 2008; 48:841-52. [PMID: 18752325 PMCID: PMC2929828 DOI: 10.1002/hep.22401] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
UNLABELLED Concanavalin A (Con A)-induced injury is an established natural killer T (NKT) cell-mediated model of inflammation that has been used in studies of immune liver disease. Extracellular nucleotides, such as adenosine triphosphate, are released by Con A-stimulated cells and bind to specific purinergic type 2 receptors to modulate immune activation responses. Levels of extracellular nucleotides are in turn closely regulated by ectonucleotidases, such as CD39/NTPDase1. Effects of extracellular nucleotides and CD39 on NKT cell activation and upon hepatic inflammation have been largely unexplored to date. Here, we show that NKT cells express both CD39 and CD73/ecto-5'-nucleotidase and can therefore generate adenosine from extracellular nucleotides, whereas natural killer cells do not express CD73. In vivo, mice null for CD39 are protected from Con A-induced liver injury and show substantively lower serum levels of interleukin-4 and interferon-gamma when compared with matched wild-type mice. Numbers of hepatic NKT cells are significantly decreased in CD39 null mice after Con A administration. Hepatic NKT cells express most P2X and P2Y receptors; exceptions include P2X3 and P2Y11. Heightened levels of apoptosis of CD39 null NKT cells in vivo and in vitro appear to be driven by unimpeded activation of the P2X7 receptor. CONCLUSION CD39 and CD73 are novel phenotypic markers of NKT cells. In turn, CD39 expression [corrected] modulates nucleotide-mediated cytokine production by, and limits apoptosis of, hepatic NKT cells. Deletion of CD39 is protective in [corrected] Con A-induced hepatitis. This study illustrates a [corrected] role for purinergic signaling in NKT-mediated mechanisms that result in liver immune injury.
Collapse
Affiliation(s)
- Guido Beldi
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA,Department of Visceral and Transplant Surgery, Inselspital, University Hospital, Bern, Switzerland
| | - Yan Wu
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| | - Yara Banz
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| | - Michael Nowak
- Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Lindsay Miller
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| | - Keiichi Enjyoji
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| | - Arvand Haschemi
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| | - Gennady G. Yegutkin
- MediCity Research Laboratory, University of Turku, National Public Health Institute, Turku, Finland
| | - Daniel Candinas
- Department of Visceral and Transplant Surgery, Inselspital, University Hospital, Bern, Switzerland
| | - Mark Exley
- Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Simon C. Robson
- Liver and Transplantation Centers, Department of Medicine, Harvard Medical School, Boston, MA
| |
Collapse
|
38
|
Rosenmeier JB, Yegutkin GG, González-Alonso J. Activation of ATP/UTP-selective receptors increases blood flow and blunts sympathetic vasoconstriction in human skeletal muscle. J Physiol 2008; 586:4993-5002. [PMID: 18703581 DOI: 10.1113/jphysiol.2008.155432] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Sympathetic vasoconstriction is blunted in the vascular beds of contracting skeletal muscle in humans, presumably due to the action of vasoactive metabolites (functional sympatholysis). Recently, we demonstrated that infusion of ATP into the arterial circulation of the resting human leg increases blood flow and concomitantly blunts alpha-adrenergic vasoconstriction in a similar manner to that during moderate exercise. Here we tested the hypothesis that ATP, rather than its dephosphorylated metabolites, induces vasodilatation and sympatholysis in resting skeletal muscle via activation of ATP/UTP-selective receptors. To this aim, we first measured leg blood flow (LBF), mean arterial pressure (MAP), cardiac output , leg arterial-venous (a-v) O(2) difference, plasma ATP and soluble nucleotidase activities during intrafemoral artery infusion of adenosine, AMP, ADP, ATP or UTP in nine healthy males. Comparison of the doses of nucleotides and adenosine required for a similar increase in LBF from approximately 0.5 l min(-1) at baseline to approximately 3.5 l min(-1) (without altering MAP but increasing Q significantly) revealed the following rank order of vasoactive potency: ATP (100) = UTP (100) >> adenosine (5.8) > ADP (2.7) > AMP (1.7). The infusions did not cause any shifts in plasma ATP level or soluble serum nucleotidase activities. Combined infusion of the vasodilatory compounds and the sympathetic vasoconstrictor drug tyramine increased plasma noradrenaline in all hyperaemic conditions, but only caused leg and systemic vasoconstriction and augmented O(2) extraction during adenosine, AMP and ADP infusion (LBF from 3.2 +/- 0.3 to 1.8 +/- 0.2 l min(-1); 3.7 +/- 0.4 to 1.7 +/- 0.2 l min(-1) and 3.3 +/- 0.4 to 2.4 +/- 0.3 l min(-1), respectively, P < 0.05). These findings in humans suggest that the vasodilatory and sympatholytic effects of exogenous ATP in the skeletal muscle vasculature are largely mediated via ATP itself rather than its dephosphorylated metabolites, most likely via binding to endothelial ATP/UTP-selective P2Y(2) receptors. These data are consistent with a role of ATP in skeletal muscle hyperaemia in conditions of increased sympathetic nerve drive such as exercise or hypoxia.
Collapse
Affiliation(s)
- Jaya B Rosenmeier
- Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen Ø, Denmark.
| | | | | |
Collapse
|
39
|
Mikhailov A, Sokolovskaya A, Yegutkin GG, Amdahl H, West A, Yagita H, Lahesmaa R, Thompson LF, Jalkanen S, Blokhin D, Eriksson JE. CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol 2008; 181:464-75. [PMID: 18566412 DOI: 10.4049/jimmunol.181.1.464] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The molecular mechanisms underlying the multiresistant phenotype of leukemic and other cancer cells are incompletely understood. We used expression arrays to reveal differences in the gene expression profiles of an apoptosis-resistant T cell leukemia clone (A4) and normally apoptosis-sensitive parental Jurkat cells. CD73 (ecto-5'-nucleotidase) was the most up-regulated gene in the resistant A4 cell clone. A4 cells displayed CD73 surface expression and significant ecto-5'-nucleotidase activity. The role of CD73 was confirmed by transfection of wild-type CD73 into native Jurkat cells, which led to specific resistance against TRAIL-induced apoptosis, but not other types of apoptosis. The protective role of CD73 was further confirmed by small interfering RNA-mediated down-regulation of CD73, restoring TRAIL sensitivity. CD73-mediated resistance was independent of enzymatic activity of CD73, but was reliant on the anchoring of the protein to the membrane via GPI. We suggest that the inhibition of TRAIL signaling works through interaction of CD73 with death receptor 5, as CD73 and death receptor 5 could be coimmunoprecipitated and were shown to be colocalized in the plasma membrane by confocal microscopy. We propose that CD73 is a component of multiresistance machinery, the transcription of which is activated under selective pressure of the immune system.
Collapse
Affiliation(s)
- Andrey Mikhailov
- Turku Centre for Biotechnology, University of Turku/Abo Akademi University, Turku, Finland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Changes in endothelial permeability are crucial in the pathogenesis of many diseases. Adenosine is one of the endogenous mediators controlling endothelial permeability under normal conditions, and an endothelial cell surface enzyme CD73 is a key regulator of adenosine production. Here we report that IFN-beta is a novel inducer of CD73. We found that pretreatment with IFN-beta dramatically improved the vascular barrier function in lungs after intestinal ischemia-reperfusion injury in wild-type animals in vivo. IFN-beta had absolutely no protective effects in CD73-deficient mice, which suffered from more severe lung damage than wild-type mice, showing that IFN-beta functions strictly in a CD73-dependent manner. Most importantly, IFN-beta treatment initiated after the ischemic period almost completely inhibited vascular leakage during the reperfusion. IFN-beta also induced the expression and activity of CD73 and concurrently decreased vascular permeability in cultured human pulmonary endothelial cells. These data show that induction of CD73 and improvement of vascular barrier are new mechanisms for the anti-inflammatory action of IFN-beta. Moreover, IFN-beta treatment may be useful in alleviating vascular leakage induced by ischemia-reperfusion injury.
Collapse
Affiliation(s)
- Jan Kiss
- MediCity Research Laboratory, University of Turku, Department of Medical Microbiology, and Turku University Hospital, Department of Surgery, Finland
| | | | | | | | | | | |
Collapse
|
41
|
Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783:673-94. [PMID: 18302942 DOI: 10.1016/j.bbamcr.2008.01.024] [Citation(s) in RCA: 851] [Impact Index Per Article: 53.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2007] [Revised: 01/15/2008] [Accepted: 01/22/2008] [Indexed: 12/19/2022]
Abstract
The involvement of extracellular nucleotides and adenosine in an array of cell-specific responses has long been known and appreciated, but the integrative view of purinergic signalling as a multistep coordinated cascade has emerged recently. Current models of nucleotide turnover include: (i) transient release of nanomolar concentrations of ATP and ADP; (ii) triggering of signalling events via a series of ligand-gated (P2X) and metabotropic (P2Y) receptors; (iii) nucleotide breakdown by membrane-bound and soluble nucleotidases, including the enzymes of ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family, ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) family, ecto-5'-nucleotidase/CD73, and alkaline phosphatases; (iv) interaction of the resulting adenosine with own nucleoside-selective receptors; and finally, (v) extracellular adenosine inactivation via adenosine deaminase and purine nucleoside phosphorylase reactions and/or nucleoside uptake by the cells. In contrast to traditional paradigms that focus on purine-inactivating mechanisms, it has now become clear that "classical" intracellular ATP-regenerating enzymes, adenylate kinase, nucleoside diphosphate (NDP) kinase and ATP synthase can also be co-expressed on the cell surface. Furthermore, data on the ability of various cells to retain micromolar ATP levels in their pericellular space, as well as to release other related compounds (adenosine, UTP, dinucleotide polyphosphates and nucleotide sugars) gain another important insight into our understanding of mechanisms regulating a signalling cascade. This review summarizes recent advances in this rapidly evolving field, with particular emphasis on the nucleotide-releasing and purine-converting pathways in the vasculature.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku and National Public Health Institute, Turku, Finland.
| |
Collapse
|
42
|
Yegutkin GG, Samburski SS, Mortensen SP, Jalkanen S, González-Alonso J. Intravascular ADP and soluble nucleotidases contribute to acute prothrombotic state during vigorous exercise in humans. J Physiol 2007; 579:553-64. [PMID: 17204504 PMCID: PMC2075398 DOI: 10.1113/jphysiol.2006.119453] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Extracellular ATP and ADP trigger vasodilatatory and prothrombotic signalling events in the vasculature. Here, we tested the hypothesis that nucleotide turnover is activated in the bloodstream of exercising humans thus contributing to the enhanced platelet reactivity and haemostasis. Right atrial, arterial and venous blood samples were collected from endurance-trained athletes at rest, during submaximal and maximal cycle ergometer exercise, and after early recovery. ATP-specific bioluminescent assay, together with high-performance liquid chromatographic analysis, revealed that plasma ATP and ADP concentrations increased up to 2.5-fold during maximal exercise. Subsequent flow cytometric analysis showed that plasma from exercising subjects significantly up-regulated the surface expression of P-selectin in human platelets and these prothrombotic effects were diminished after scavenging plasma nucleotides with exogenous apyrase. Next, using thin layer chromatographic assays with [gamma-(32)P]ATP and (3)H/(14)C-labelled nucleotides, we showed that two soluble nucleotide-inactivating enzymes, nucleotide pyrophosphatase/phosphodiesterase and nucleoside triphosphate diphosphohydrolase, constitutively circulate in human bloodstream. Strikingly, serum nucleotide pyrophosphatase and hydrolase activities rose during maximal exercise by 20-25 and 80-100%, respectively, and then declined after 30 min recovery. Likewise, soluble nucleotidases were transiently up-regulated in the venous blood of sedentary subjects during exhaustive exercise. Human serum also contains 5'-nucleotidase, adenylate kinase and nucleoside diphosphate (NDP) kinase; however, these activities remain unchanged during exercise. In conclusion, intravascular ADP significantly augments platelet activity during strenuous exercise and these prothrombotic responses are counteracted by concurrent release of soluble nucleotide-inactivating enzymes. These findings provide a novel insight into the mechanisms underlying the enhanced risk of occlusive thrombus formation under exercising conditions.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory, University of Turku, National Public Health Institute, Turku, Finland.
| | | | | | | | | |
Collapse
|
43
|
Marttila-Ichihara F, Smith DJ, Stolen C, Yegutkin GG, Elima K, Mercier N, Kiviranta R, Pihlavisto M, Alaranta S, Pentikäinen U, Pentikäinen O, Fülöp F, Jalkanen S, Salmi M. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. ACTA ACUST UNITED AC 2006; 54:2852-62. [PMID: 16947396 DOI: 10.1002/art.22061] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
OBJECTIVE Leukocyte traffic from the blood to the joints is crucial in the pathogenesis of arthritis. A bifunctional endothelial cell-surface glycoprotein, AOC3 (amine oxidase, copper-containing 3; also known as vascular adhesion protein 1), has both adhesive and enzymatic properties. We undertook this study to determine the contribution of AOC3 and its oxidase activity to leukocyte trafficking into inflamed joints in vivo. METHODS We used gene-modified animals, molecular modeling, an AOC3 enzyme inhibitor, oxidase assays, and arthritis models (adjuvant-induced arthritis [AIA] in rats and anti-type II collagen antibody-induced arthritis in mice) to dissect the importance of AOC3 in vivo. RESULTS The AOC3 inhibitor fitted well with a covalent binding mode into the active site of the AOC3 crystal structure. It selectively blocked the oxidase activity of AOC3 in enzyme assays. Intraperitoneal and oral administration of the AOC3 inhibitor significantly ameliorated rat AIA. In anti-type II collagen antibody-induced arthritis in mice, the AOC3 inhibitor also improved the outcome of the joint inflammation. The acute semicarbazide-sensitive amine oxidase blockade by the inhibitor had even more pronounced effects than genetic deletion of AOC3. Enzymatic analyses showed that the inhibitor also blocked 2 other structurally very closely related AOCs, but not any of more than 100 other enzymes tested. CONCLUSION These are the first data to demonstrate that the enzymatic activity of the atypical endothelial adhesion molecule AOC3, and possibly that of other closely related ecto-oxidases, is crucial for leukocyte exit from the vessels in inflamed joints in vivo.
Collapse
|
44
|
Abstract
Pancreatic acini release ATP in response to various stimuli, including cholecystokinin octapeptide (CCK-8), as we show in the present study. There were indications that pancreatic juice also contains enzymes that could hydrolyze ATP during its passage through the ductal system. The aim of this study was to determine which ATP-degrading and possibly ATP-generating enzymes were present in pancreatic secretion. For this purpose, pancreatic juice was collected from anesthetized rats stimulated with infusion of CCK-8. Purine-converting activities in juice samples were assayed by TLC using either [gamma-(32)P]ATP or (14)C/(3)H-labeled and unlabeled nucleotides as appropriate substrates. Data show that the juice contains the enzyme ecto-nucleoside triphosphate diphosphohydrolase that can hydrolyze both [(14)C]ATP and [(3)H]ADP about equally well, i.e. CD39. Reverse-phase high-performance liquid chromatography analysis additionally shows that this enzyme has broad substrate specificity toward other nucleotides, UTP, UDP, ITP, and IDP. In addition, secretion contains ecto-5'-nucleotidase, CD73, further converting [(3)H]AMP to adenosine. Along with highly active hydrolytic enzymes, there were also ATP-generating enzymes in pancreatic juice, adenylate kinase, and NDP kinase, capable of sequentially phosphorylating AMP via ADP to ATP. Activities of nonspecific phosphatases, nucleotide pyrophosphatase/phosphodiesterases, and adenosine deaminase were negligible. Taken together, CCK-8 stimulation of pancreas causes release of both ATP-consuming and ATP-generating enzymes into pancreatic juice. This newly discovered richness of secreted enzymes underscores the importance of purine signaling between acini and pancreatic ducts lumen and implies regulation of the purine-converting enzymes release.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Research Laboratory and Department of Medical Microbiology, Turku University and National Public Health Institute, FIN-2050 Turku, Finland
| | | | | | | |
Collapse
|
45
|
Yegutkin GG, Mikhailov A, Samburski SS, Jalkanen S. The detection of micromolar pericellular ATP pool on lymphocyte surface by using lymphoid ecto-adenylate kinase as intrinsic ATP sensor. Mol Biol Cell 2006; 17:3378-85. [PMID: 16707571 PMCID: PMC1525232 DOI: 10.1091/mbc.e05-10-0993] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Current models of extracellular ATP turnover include transient release of nanomolar ATP concentrations, triggering of signaling events, and subsequent ectoenzymatic inactivation. Given the high substrate specificity for adenylate kinase for reversible reaction (ATP + AMP <--> 2ADP), we exploited lymphoid ecto-adenylate kinase as an intrinsic probe for accurate sensing pericellular ATP. Incubation of leukemic T- and B-lymphocytes with [3H]AMP or [alpha-32P]AMP induces partial nucleotide conversion into high-energy phosphoryls. This "intrinsic" AMP phosphorylation occurs in time- and concentration-dependent fashions via nonlytic supply of endogenous gamma-phosphate-donating ATP, remains relatively resistant to bulk extracellular ATP scavenging by apyrase, and is diminished after lymphocyte pretreatment with membrane-modifying agents. This enzyme-coupled approach, together with confocal imaging of quinacrine-labeled ATP stores, suggests that, along with predominant ATP accumulation within cytoplasmic granules, micromolar ATP concentrations are constitutively retained on lymphoid surface without convection into bulk milieu. High basal levels of inositol phosphates in the cells transfected with ATP-selective human P2Y2-receptor further demonstrate that lymphocyte-surrounding ATP is sufficient for triggering purinergic responses both in autocrine and paracrine fashions. The ability of nonstimulated lymphocytes to maintain micromolar ATP halo might represent a novel route initiating signaling cascades within immunological synapses and facilitating leukocyte trafficking between the blood and tissues.
Collapse
Affiliation(s)
- Gennady G Yegutkin
- MediCity Laboratory and Department of Medical Microbiology, Turku University and National Public Health Institute, FIN-20520 Turku, Finland.
| | | | | | | |
Collapse
|
46
|
Stolen CM, Marttila-Ichihara F, Koskinen K, Yegutkin GG, Turja R, Bono P, Skurnik M, Hänninen A, Jalkanen S, Salmi M. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005; 22:105-15. [PMID: 15664163 DOI: 10.1016/j.immuni.2004.12.006] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2004] [Revised: 11/24/2004] [Accepted: 12/01/2004] [Indexed: 10/25/2022]
Abstract
Leukocyte migration from the blood to tissues is a prerequisite for normal immune responses. We produced mice deficient in an endothelial cell-surface oxidase (amine oxidase, copper containing-3 [AOC3], also known as vascular adhesion protein-1 [VAP-1]) and found that this enzyme is needed for leukocyte extravasation in vivo. Real-time imaging shows that AOC3 mediates slow rolling, firm adhesion, and transmigration of leukocytes in vessels at inflammatory sites and lymphoid tissues. Absence of AOC3 results in reduced lymphocyte homing into lymphoid organs and in attenuated inflammatory response in peritonitis. These data alter the paradigm of leukocyte extravasation cascade by providing the first physiological proof for the concept that endothelial cell surface enzymes regulate the development of inflammatory reactions in vivo and suggest that this enzyme should be useful as an anti-inflammatory target.
Collapse
Affiliation(s)
- Craig M Stolen
- Department of Medical Microbiology, MediCity Research Laboratory, National Public Health Institute, Turku University, 20520 Turku, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Yegutkin GG, Salminen T, Koskinen K, Kurtis C, McPherson MJ, Jalkanen S, Salmi M. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress. Eur J Immunol 2004; 34:2276-85. [PMID: 15259025 DOI: 10.1002/eji.200424932] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Vascular adhesion protein-1 (VAP-1) is an endothelial adhesion molecule mediating leukocyte interactions with blood vessels during leukocyte extravasation. Molecularly VAP-1 is a cell-surface-expressed ecto-enzyme belonging to the group of semicarbazide-sensitive amine oxidases (SSAO; EC 2.4.6.3), which deaminate primary amines. Here we asked whether peptides displaying a suitable free amine group could be a substrate or inhibitor of SSAO and thus regulate VAP-1-mediated leukocyte adhesion. On the basis of a molecular model of VAP-1, we designed synthetic peptides that fit to the substrate channel of VAP-1. One of these lysine-containing peptides effectively inhibits VAP-1-dependent lymphocyte rolling and firm adhesion to primary endothelial cells under physiologically relevant shear conditions. The same peptide inhibits the SSAO activity of endothelial and recombinant VAP-1 in a selective and long-lasting manner. We also show that all enzymatically active VAP-1 is displayed on the cell surface. Our results suggest that, in addition to soluble amines, specific cell-surface-bound molecules containing free NH(2) groups in a suitable position may modulate the enzymatic activity of SSAO. Moreover, the inhibitory peptide diminishes leukocyte interactions with endothelial cells under conditions of shear, and thus it may be useful to treat inflammatory conditions.
Collapse
|
48
|
Abstract
Semicarbazide-sensitive amine oxidases (SSAO) are enzymes that are capable of deaminating primary amines to produce aldehyde, ammonia, and hydrogen peroxide. This activity has been associated with vascular adhesion protein-1 (VAP-1) and is found in the serum, endothelium, adipose, and smooth muscle of mammals. Circulating SSAO activity is increased in congestive heart failure, diabetes, and inflammatory liver diseases. To investigate the origin of circulating SSAO activity, two transgenic mouse models were created with full-length human VAP-1 (hVAP-1) expressed on either endothelial (mTIEhVAP-1) or adipose tissues (aP2hVAP-1), with tie-1 and adipocyte P2 promoters, respectively. Under normal conditions a circulating form of hVAP-1 was found at high levels in the serum of mice with endothelium-specific expression and at low levels in the serum of mice with adipose specific expression. The level of circulating hVAP-1 in the transgenic mice varied with gender, transgene zygosity, diabetes, and fasting. Serum SSAO activity was absent from VAP-1 knockout mice and endothelial cell-specific expression of human VAP-1 restored SSAO activity to the serum of VAP-1 knockout mice. Together, these experiments show that in the mouse VAP-1 is the only source of serum SSAO, that under physiological conditions vascular endothelial cells can be a major source of circulating VAP-1 protein and SSAO, and that serum VAP-1 can originate from both endothelial cells and adipocytes during experimental diabetes. An increased endothelial cell capacity for lymphocyte binding and altered expression of redox-sensitive proteins was also associated with the mTIEhVAP-1 transgene.
Collapse
Affiliation(s)
- Craig M Stolen
- MediCity Research Laboratory, University of Turku and National Public Health Institute, Tykistökatu 6A, FIN-20520, Turku, Finland.
| | | | | | | | | | | |
Collapse
|
49
|
Niemelä J, Henttinen T, Yegutkin GG, Airas L, Kujari AM, Rajala P, Jalkanen S. IFN-alpha induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5'-nucleotidase) up-regulation. J Immunol 2004; 172:1646-53. [PMID: 14734746 DOI: 10.4049/jimmunol.172.3.1646] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CD73 (ecto-5'-nucleotidase; EC 3.1.3.5) participates in lymphocyte binding to endothelial cells and converts extracellular AMP into a potent anti-inflammatory substance adenosine. However, the regulation of expression and function of CD73 has remained largely unknown. In this study, we show that IFN-alpha produces a time- and dose-dependent long-term up-regulation of CD73 on endothelial cells, but not on lymphocytes both at protein and RNA levels. Moreover, CD73-mediated production of adenosine is increased after IFN-alpha treatment on endothelial cells, resulting in a decrease in the permeability of these cells. Subsequent to induction with PMA, FMLP, dibutyryl cAMP, thrombin, histamine, IL-1beta, TNF-alpha, and LPS, no marked changes in the level of CD73 expression on endothelial cells are observed. We also show that CD73 is up-regulated in vivo on the vasculature after intravesical treatment of urinary bladder cancers with IFN-alpha. In conclusion, distinct behavior of lymphocyte and endothelial CD73 subsequent to cytokine treatment further emphasizes the existence of cell type-specific mechanisms in the regulation of CD73 expression and function. Overall, these results suggest that IFN-alpha is a relevant in vivo regulator of CD73 in the endothelial-leukocyte microenvironment in infections/inflammations, and thus has a fundamental role in controlling the extent of inflammation via CD73-dependent adenosine production.
Collapse
Affiliation(s)
- Jussi Niemelä
- MediCity Research Laboratory and Department of Medical Microbiology, Turku University, Turku, Finland
| | | | | | | | | | | | | |
Collapse
|
50
|
Stolen CM, Madanat R, Marti L, Kari S, Yegutkin GG, Sariola H, Zorzano A, Jalkanen S. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 2004; 18:702-4. [PMID: 14977883 DOI: 10.1096/fj.03-0562fje] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Semicarbazide-sensitive amine oxidases (SSAO) are copper-containing enzymes that oxidatively deaminate primary amines to produce hydrogen peroxide, ammonium, and specific aldehydes. Vascular adhesion protein-1 (VAP-1) is a cell surface and soluble molecule that possesses SSAO activity. VAP-1 protein, SSAO activity, and SSAO reaction products are elevated in the serum of patients with diabetes, congestive heart failure, and specific inflammatory liver diseases. By expressing human VAP-1/SSAO on mouse endothelial cells and subsequently in the serum, and by chronically treating the transgenic mice for 15 months with a high-fat diet and a physiological substrate for SSAO, methylamine, the in vivo roles of SSAO were assessed. The VAP-1 transgene increased the mouse body mass index and subcutaneous abdominal fat pad weights in a manner independent of food consumption. The transgene together with increased SSAO substrate availability enhanced glucose uptake in an SSAO-dependent manner. The increased SSAO activity also led to diabetes-like complications, including advanced glycation end product formation, elevated blood pressure, altered atherosclerosis progression, and nephropathy. These findings suggest that, although manipulation of VAP-1/SSAO has potential to serve as a therapeutic treatment in insulin-resistant conditions, care must be taken to fully understand its impact on obesity and vascular damage.
Collapse
Affiliation(s)
- Craig M Stolen
- MediCity Research Laboratory, University of Turku and National Public Health Institute, Turku, Finland.
| | | | | | | | | | | | | | | |
Collapse
|